UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2018~~2019

		OR

	☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934

For the transition period from ___________to ____________

Commission File Number 000-55345

ZERO GRAVITY SOLUTIONS, INC. (Exact name of ~~business~~registrant as specified in its charter)

NEVADA

46-1779352

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer Identification No.)

190 NW SPANISH RIVER BOULEVARD, SUITE 101, BOCA RATON, FLORIDA 33431

(Address, including zip code, of principal executive offices)

(561) 416-0400

(~~Issuer~~Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None.

Title of each class = Trading Symbol(s) = Name of each exchange on which registered

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ ☐ No ☐☒ The Company has not filed its Quarterly Report on Form 10-Q for the quarterly periods ended June 30, 2019, September 30, 2019 and March 31, 2020 and it's Annual report on Form 10-K for the year ended December 31, 2019.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files).

Yes ☒ ☐ No ☐☒ See above

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐☒ ~~(Do not check if a smaller reporting company)~~ Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of ~~November~~July 1831, ~~2018~~2020, the issuer had 4039,~~954~~678,~~115~~ 555 shares of common stock issued and outstanding.

Table of Contents

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION 2 Item 1. Condensed Consolidated Financial Statements (unaudited) 2 Condensed Consolidated Balance Sheets as of September 30, 2018 (unaudited) and December 31, 2017 2 Condensed Consolidated Statements of Operations for the Three Months and Nine Months Ended September 30, 2018 and September 30, 2017 (unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and September 30, 2017 (unaudited) 4 Notes to Condensed Consolidated Financial Statements (unaudited) 5 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3. Quantitative & Qualitative Disclosures about Market Risks 30 Item 4. Controls and Procedures 30 PART II OTHER INFORMATION 31 Item 1. Legal Proceedings 31 Item 1A. Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults upon Senior Securities 31 Item 5. Other Information 31 Item 6. Exhibits 31

PART I. FINANCIAL INFORMATION	2

Item 1. Condensed Consolidated Financial Statements (unaudited)	2

Condensed Consolidated Balance Sheets as of March 31, 2019 (unaudited) and December 31, 2018	2

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2019 and March 31, 2018 (unaudited)	3

Consolidated Statements of Changes in Stockholders' Deficit or for the Three Months Ended March 31, 2019 and March 31, 2018 (unaudited)	4

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2019 and March 31, 2018 (unaudited)	5

Notes to Condensed Consolidated Financial Statements (unaudited)	6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	26

Item 3. Quantitative & Qualitative Disclosures about Market Risks	33

Item 4. Controls and Procedures	34

PART II OTHER INFORMATION	35

Item 1. Legal Proceedings	35

Item 1A. Risk Factors	35

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	35

Item 3. Defaults upon Senior Securities	35

Item 5. Other Information	35

Item 6. Exhibits	36

Table of Contents

CAUTIONARY STATEMENT ON FORWARD-LOOKING STATEMENTS

Statements in this report may be "forward-looking statements." within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements discuss matters that are not historical facts. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in this report, including the risks described under "Risk Factors" and any risks described in any other filings we make with the SEC. ~~Any~~including ~~forward-looking~~our ~~statements~~Annual ~~speak~~Report ~~only as of the date~~ on ~~which~~Form ~~they are made, and we do not undertake any obligation to update any forward~~10-~~looking~~K ~~statement~~for ~~to reflect events or circumstances after~~ the ~~date~~year ofended ~~this~~December ~~report~~31, 2018.

These factors include, among others:

● current or future financial performance;
● management’s plans and objectives for future operations;
● uncertainties associated with product research and development;
● uncertainties associated with dependence upon the actions of government regulatory agencies;
● product plans and performance;
● management’s assessment of market factors; and
● statements regarding our strategy and plans.

We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements are found at various places throughout this report and include information concerning possible or assumed future results of our operations, including statements about business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future acquisitions, future cash needs, future operations, business plans and future financial results, and any other statements that are not historical facts. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. All subsequent written and oral forward-looking statements concerning other matters addressed in this report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this report. Any forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report.

Management’s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, we evaluate these estimates, including those related to useful lives of property and equipment, the allowance for doubtful accounts and stock based compensation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There can be no assurance that actual results will not differ from those estimates.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. CONDENSED Consolidated Financial Statements

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

	September 30, 2018			December 31, 2017
	March 31, 2019			December 31, 2018
	(unaudited)
ASSETS
CURRENT ASSETS
Cash	$	~~382~~3,~~231~~187		$	1343,~~862~~683
Accounts receivable, net		~~443~~-			~~1,393~~342
Prepaid expenses		~~146~~304,~~390~~101			~~216~~314,~~139~~645
Inventory		75125,~~928~~901			68103,~~643~~142
Total current assets		~~604~~433,~~992~~189			~~300~~461,~~037~~812
Property and equipment, net		8979,~~845~~192			~~104~~85,~~590~~523
OTHER ASSETS
Deposits		4,817			4,~~617~~817
Intellectual property, net		10,522			11,458
Total other assets		4,817			4,817
Advance on future royalties - related parties, net		-			319,441
TOTAL ASSETS	$	517,198		$	552,152
Total other assets		15,339			335,516
TOTAL ASSETS	$	710,176		$	740,143
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable and other payables	$	~~290~~674,~~115~~829		$	~~693~~544,~~695~~659
Accounts payable, related party		6796,~~069~~826			80127,~~097~~480
Accrued interest		1649,~~870~~629			221,~~500~~262
Accrued interest, related party		99204,~~289~~869			32100,~~250~~919
Deferred compensation, related party		12,500			12,500
Deferred revenue		206,800			250,000
Convertible Note payable - related party		500,000			500,000
Deferred compensation, related party		-			12,500
Note payable		38,706			204,419
Insurance financing liability		168,819			223,482
Total liabilities (all current)		1,024,549			1,525,461
Notes payable, related party, net of discounts $53,289 and $41,379		1,846,711			1,058,621
Convertible notes payable, net of discounts $198,504 and $127,053		101,996			8,947
Convertible notes payable, related party		925,000			500,000
Notes payable, net of discounts $9,451 and $8,892		290,549			191,108
Embedded conversion option liability		231,000			114,000
Total current liabilities		4,797,028			3,152,978
LONG TERM LIABILITIES
Note payable, net of discount of $15,880 and $18,218		284,120			181,782
Notes payable, net of discounts $0 and $3,737		-			96,263
Notes payable, related parties, net of discount of $125,547 and $97,796		1,974,456			1,002,204
Notes payable, related parties, net of discounts $17,289 and $56,380		282,712			943,621
Convertible Note payable, net of discount of $224,080 and $0		325,920			-
Convertible notes payable, net of discounts $162,382 and $193,202		387,618			356,794
Convertible Note payable - related party, net of discount of $585,211 and $0		914,789			-
Convertible notes payable, related parties, net of discounts $418,856 and $501,351		1,181,144			1,098,649
Total long-term liabilities		31,~~499~~851,~~285~~474			12,~~183~~495,~~986~~327
Total Liabilities		46,~~523~~648,~~834~~502			25,~~709~~648,~~447~~305
Commitments (Note 4)
STOCKHOLDERS' DEFICIT
Common stock; 100,000,000 shares authorized, at $0.001 par value, 40,954,115 and 40,650,397 shares issued and outstanding, at September 30, 2018 and December 31, 2017, respectively		40,954			40,650
Common stock; 100,000,000 shares authorized, at $0.001 par value, 41,307,310 and 40,954,115 shares issued and outstanding, at March 31, 2019 and
Additional paid-in capital		24,241,123			21,970,266
December 31, 2018, respectively		41,307			40,954
Accumulated deficit		(28,095,735	)		(23,980,220	)
Additional paid-in capital		24,479,365			24,283,509
Total stockholders' deficit		(3,813,658	)		(1,969,304	)
Accumulated deficit		(30,651,704	)		(29,420,616	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	710,176		$	740,143
Non-controlling interest		(272	)		-
Total stockholders' deficit		(6,131,304	)		(5,096,153	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	517,198		$	552,152

See accompanying notes to unaudited condensed consolidated financial statements

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations ~~(Unaudited)~~

	Three Months Ended			Three Months Ended			Nine Months Ended			Nine Months Ended
	September 30,			September 30,			September 30,			September 30,
	2018			2017			2018			2017
REVENUE
Sale of goods	$	11,635		$	4,355		$	44,705		$	65,545
Total revenue		11,635			4,355			44,705			65,545
COST OF REVENUE
Cost of goods sold		2,476			157			6,100			10,263
Royalty expense		-			218			1,654			2,092
Total cost of revenue		2,476			375			7,754			12,355
GROSS PROFIT		9,159			3,980			36,951			53,190
OPERATING EXPENSES
General and administrative		1,003,056			1,492,884			3,553,188			5,623,117
Research and development		16,710			41,041			138,625			140,030
Total operating expenses		1,019,766			1,533,925			3,691,813			5,763,147
LOSS FROM OPERATIONS		(1,010,607	)		(1,529,945	)		(3,654,862	)		(5,709,957	)
OTHER INCOME (EXPENSE)
Loss on disposal of assets		(1,197	)		-			(1,540	)		-
Interest expense		(119,673	)		(18,386	)		(253,175	)		(45,101	)
Accretion of debt discount		(132,976	)		(2,673	)		(205,938	)		(2,673	)
Foreign exchange loss		-			(387	)		-			(387	)
Total other income (expense)		(253,846	)		(21,446	)		(460,653	)		(48,161	)
NET LOSS	$	(1,264,453	)	$	(1,551,391	)	$	(4,115,515	)	$	(5,758,118	)
NET LOSS PER SHARE - BASIC AND DILUTED	$	(0.03	)	$	(0.04	)	$	(0.10	)	$	(0.15	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED		40,954,115			40,323,242			40,846,981			38,948,632

(Unaudited)

	Three Months Ended March 31,
	2019			2018
REVENUE
Sale of goods	$	44,495		$	3,470
Total revenue		44,495			3,470
COST OF REVENUE
Cost of goods sold		24,013			377
Shipping costs		3,300			-
Royalty expense		-			173
Total cost of revenue		27,313			550
GROSS PROFIT		17,182			2,920

OPERATING EXPENSES
General and administrative		886,712			1,409,696
Research and development		1,071			84,817
Total operating expenses		887,783			1,494,513
LOSS FROM OPERATIONS		(870,601	)		(1,491,593	)
OTHER INCOME (EXPENSE)
Change in fair value of derivative		(28,000	)		-
Interest expense		(135,152	)		(61,099	)
Amortization of debt discount		(197,335	)		(23,642	)
Loss on disposal of asset		-			(343	)
Total other income (expense)		(360,487	)		(85,084	)
NET LOSS	$	(1,231,088	)	$	(1,576,677	)
NET LOSS PER SHARE - BASIC AND DILUTED	$	(0.03	)	$	(0.04	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED		41,052,658			40,671,851

See accompanying notes to unaudited condensed consolidated financial statements

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

~~Condensed~~ Consolidated Statements of ~~Cash~~Changes ~~Flows~~in ~~(Unaudited)~~Stockholders’ Deficit

	Nine Months Ended
	September 30,
	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(4,115,515	)	$	(5,758,118	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		18,770			18,414
Amortization expense		936			646
Bad debt expense		4,060			-
Common stock issued for services		-			150,000
Warrants issued for services		296,271			655,128
Stock options issued as compensation		146,277			108,388
Loss on disposal of asset		1,540			-
Advance on future royalties - related parties reserve		129,580			-
Impairment expense		203,208			-
Warrant modification expense		-			926,885
Amortization of debt issuance costs		205,938			2,673
Changes in operating assets and liabilities:
Accounts receivable, trade		(3,110	)		87,693
Other current assets		-			(19,685	)
Prepaid expenses		69,749			204,771
Advance on future royalties - related parties		(13,347	)		(34,912	)
Inventory		(7,285	)		(49,210	)
Deposit		(200	)		(1,000	)
Accounts payable, related party		(13,028	)		-
Accounts payable and other payables		(403,580	)		227,537
Accrued interest, related party		14,370			-
Accrued interest		67,039			-
Net cash used in operating activities		(3,398,327	)		(3,480,791	)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid to acquire intellectual property		-			(6,976	)
Cash paid to purchase equipment		(5,489	)		(9,412	)
Net cash used in investing activities		(5,489	)		(16,388	)
CASH FLOWS FROM FINANCING ACTIVITIES
Payments of notes payable		(165,790	)		(195,355	)
Payments of notes payable - related party		(300,000	)		-
Proceeds from exercise of warrants – related party		-			1,185,000
Payment of offering costs - related party		(97,500	)		(33,750	)
Proceeds of notes payable		750,000			-
Proceeds of notes payable – related party		2,700,001			600,000
Proceeds from sale of common stock		911,154			1,977,999
Payment of offering costs		(25,680	)		(138,800	)
Net cash provided by financing activities		3,772,185			3,395,094
NET INCREASE (DECREASE) IN CASH		368,369			(102,085	)
CASH AT BEGINNING OF PERIOD		13,862			232,394
CASH AT END OF PERIOD	$	382,231		$	130,309
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
CASH PAID FOR:
Income Taxes	$	-		$	-
Interest	$	159,996		$	45,101
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Warrants issued as equity direct offering costs	$	5,771		$	168,268
Warrants issued as debt discount	$	946,244		$	-

For the Three Months ended March 31, 2019 and 2018 (Unaudited)

See accompanying notes to unaudited condensed consolidated financial statements

					Additional									Total
	Common Stock				Paid-In			Accumulated			Non-controlling			Stockholders'
	Shares		Amount		Capital			Deficit			Interest			(Deficit)

Balance December 31, 2017		40,650,397	$	40,650	$	21,970,266		$	(23,980,220	)	$	-		$	(1,969,304	)

Common stock issued for cash, net of offering costs of $1,680		55,334		55		164,267			-			-			164,322

Warrants issued for services		-		-		57,947			-			-			57,947

Warrants issued for loan costs		-		-		70,897			-			-			70,897

Stock options issued for services		-		-		71,253			-			-			71,253

Net loss for the period ended March 31, 2018		-		-		-			(1,576,677	)		-			(1,576,677	)

Balance March 31, 2018		40,705,731		40,705		22,334,630			(25,556,897	)		-			(3,181,562	)

Balance December 31, 2018		40,954,115	$	40,954	$	24,283,509		$	(29,420,616	)	$	-		$	(5,096,153	)

Common stock issued for services		45,000		45		79,905			-			-			79,950

Common stock issued upon cashless exercise of warrants		306,195		306		(306	)		-			-			-

Warrants issued for services		-		-		112,651			-			-			112,651

Stock issued for loan costs		2,000		2		3,606			-			-			3,608

Non-controlling interest		-		-		-			-			(272	)		(272	)

Net loss for the period ended March 31, 2019		-		-		-			(1,231,088	)		-			(1,231,088	)

Balance March 31, 2019		41,307,310	$	41,307	$	24,479,365		$	(30,651,704	)	$	(272	)	$	(6,131,304	)

See accompanying noted to the unaudited condensed consolidated financial statements

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Three Months Ended
	March 31,
	2019			2018

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(1,231,088	)	$	(1,576,677	)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		6,331			6,235
Amortization expense		-			372
Bad debt expense		342			4,060
Common stock issued for services		79,950			-
Warrants issued for services		23,685			57,570
Stock options issued as compensation		-			71,254
Change in fair value of derivative		28,000			-
Loss on disposal of asset		-			343
Advance on future royalties, related party reserve		-			123,560
Impairment expense		-			203,208
Accretion of debt discounts		197,335			23,642
Changes in operating assets and liabilities:
Accounts receivable, trade		-			(3,230	)
Prepaid expenses		99,510			48,851
Advance on future royalties, related party		-			(7,327	)
Inventory		(22,759	)		450
Deposit		-			(200	)
Accounts payable, related party		(30,654	)		2,403
Accounts payable and other payables		129,898			(34,556	)
Deferred compensation		(12,500	)		-
Deferred revenue		(43,200	)		-
Accrued interest, related party		103,950			18,294
Accrued interest		28,367			4,584

Net cash used in operating activities		(642,833	)		(1,057,164	)

CASH FLOWS FROM FINANCING ACTIVITIES

Payments of notes payable		(61,133	)		(49,597	)
Payments of notes payable, related party		-			(100,000	)
Proceeds from notes payable convertible		425,000			-
Proceeds from notes payable insurance		6,470			-
Payment of offering costs, related party		-			(27,000	)
Proceeds of notes payable		132,000			100,000
Proceeds of notes payable, related party		100,000			1,000,000
Proceeds from sale of common stock		-			166,002
Payment of offering costs		-			(1,680	)

Net cash provided by financing activities		602,337			1,087,725

NET (DECREASE) INCREASE IN CASH		(40,496	)		30,561

CASH AT BEGINNING OF PERIOD		43,683			13,862

CASH AT END OF PERIOD	$	3,187		$	44,423
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
CASH PAID FOR:

Income taxes	$	-		$	-
Interest	$	135,152		$	61,099

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Warrants issued as equity direct offering costs	$	-		$	377
Warrants issued as debt discount	$	-		$	71,274
Stock issued for loan costs	$	3,608		$	-
Discounts related to derivative liability	$	89,000		$	-

See accompanying notes to unaudited condensed consolidated financial statements

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of ~~operations~~Operations

Zero Gravity Solutions, Inc. (the “Company”) is aan agricultural biotechnology company focused on commercializing technology derived from and designed for spaceflight with significant applications on Earth. These technologies are focused on improving world agriculture by providing valuable solutions to challenges facing humanity including threats to world agriculture and the ability to feed the world’s rapidly growing population.

The Company owns proprietary technology for its initial commercial product, BAM-FX™® that can boost the nutritional value and enhance the immune system of food crops without the use of ~~Genetic~~genetic ~~Modification~~modification. The Company’s focus is the commercialization of BAM-FX™® in both domestic and international markets. The Company’s headquarters are located in Boca Raton, Florida.

The Company operates through two ~~wholly owned~~ subsidiaries: BAM Agricultural Solutions, Inc. ~~and~~a ~~Zero~~Florida ~~Gravity~~corporation ~~Life~~(“BAM”), ~~Sciences~~which was formed in 2014, and Specialty Agricultural Solutions, Inc. (“SASI”), ~~both~~which ~~Florida~~was ~~corporations~~ formed byin ~~the~~2018 ~~Company~~and began operations in ~~2014~~2019. The Company owns 98% of SASI.

Another subsidiary of the Company, Zero Gravity Life Sciences, Inc., a Florida corporation (“ZGLS”), was formed by the Company in 2014. ZGLS is currently inactive.

The ongoing COVID-19 global and national health emergency has caused significant disruption in the international and United States economies and financial markets. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The spread of COVID-19 has caused illness, quarantines, cancellation of events and travel, business and school shutdowns, reduction in business activity and financial transactions, labor shortages, supply chain interruptions and overall economic and financial market instability. The COVID-19 pandemic has the potential to significantly impact the Company’s supply chain, distribution centers, or logistics and other service providers. During the first quarter of 2020, the Company furloughed all employees other than the three executive officers to the COVID-19 impact on its operation capability. Beginning in the second quarter of 2020 the company began to remove certain employees from furlough that are key to ongoing operations. The Company is not able to estimate the duration of the pandemic and potential impact on the business if disruptions or delays in shipments of product occur. To date, the Company has experienced product shipment delays due to import restrictions imposed by countries in which the Company had customer purchase commitments. In addition, a severe prolonged economic downturn could result in a variety of risks to the business, including weakened demand for product and a decreased ability to raise additional capital when needed on acceptable terms, if at all. As the situation continues to evolve, the Company will continue to closely monitor market conditions and respond accordingly.

Going Concern and Management’s Plans

AtThese ~~September~~interim 30, 2018, the Company had an approximate cash balance of $382,000, a working capital deficiency of approximately $(420,000), a loss from operations of approximately $(4,116,000), and negative cash flows from operating activities of approximately $(3,398,000). To date, the Company has relied on equity financing and has entered into related and non-related party promissory notes to fund its operations. The Company has also issued stock-based compensation in exchange for services. Although the Company intends to raise additional capital, the Company expects to continue to incur losses from operations and have negative cash flows from operating activities for the near-term and these losses could be significant as product development, regulatory, contract research, and technical marketing personnel related expenses are incurred. Management has evaluated its ability to continue as a going concern for the next twelve months from the issuance of these September 30, 2018 unaudited condensed consolidated financial statements, ~~and~~are ~~has~~prepared ~~determined~~on ~~that there is substantial doubt as to its ability to continue as~~ a going concern. ~~The~~basis ~~Company~~which ~~has~~contemplates satisfied its obligations using cash from successful capital raising efforts through September 30, 2018, however, there are no assurances that such successful efforts will continue for up to a year after these unaudited condensed consolidated financial statements are issued. The unaudited condensed consolidated financial statements do not include any adjustments to reflect the ~~possible~~realization ~~future effects on the recoverability and classification~~ of assets ~~or the amounts~~ and ~~classifications~~settlements of liabilities ~~that may result should the Company be unable to continue as a going concern. The Company has executed product distribution agreements with domestic~~ and ~~international~~commitments ~~commercial~~in ~~agricultural distributors and generated initial product orders. Additional technical and marketing effort must be devoted to those distributors to insure~~ the ~~product~~normal iscourse properly utilized and validated by end users. To fund these capital needs, the Company has and continues to raise capital through private placement offerings, conducted through it's own efforts or through the efforts of an investment bank, as well as raising funds through issuances of debt, to related and non-related parties. If the Company does not obtain additional capital, the Company would potentially be required to reduce the scope of its business ~~development activities or cease operations~~. ~~The Company continues to explore obtaining additional capital financing and the Company is closely monitoring its cash balances, cash needs and expense levels.~~

The Company has a working capital deficiency as of March 31, 2019, and a net loss and negative cash flows from operating activities for the three months then ended. At March 31, 2019, the Company had an approximate cash balance of $3,000 and a working capital deficiency of approximately $(4,364,000) and had net loss of approximately $(1,231,000), and negative cash flows from operating activities of approximately $(643,000) for the three months ended March 31, 2019. To date, the Company has relied on equity financing and has entered into related and non-related party promissory notes to fund its operations. The Company has also issued stock-based compensation in exchange for services. Although the Company intends to raise additional capital, the Company expects to continue to incur losses from operations and have negative cash flows from operating activities for the near-term and these losses could be significant as product development, regulatory, contract research, and technical marketing personnel related expenses are incurred. Management has evaluated its ability to continue as a going concern for the next twelve months from the issuance of these interim, condensed consolidated unaudited financial statements, and has determined that there is substantial doubt as to its ability to continue as a going concern. The Company has satisfied its obligations using cash from successful capital raising efforts through March 31, 2019; however, there are no assurances that such successful efforts will continue for up to a year after these consolidated financial statements are issued. These interim unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern. The Company has executed product distribution agreements with domestic and international commercial agricultural distributors and generated initial product orders. Additional technical and marketing efforts must be devoted to those distributors to ensure the product is properly utilized and validated by end users. To fund these capital needs, the Company has and continues to raise capital through a private placement offering in connection with its investment banker and through its internal efforts, as well as through issuances of debt. Subsequent to March 31, 2019, the Company has raised approximately $3,824,000 (Note 7). If the Company does not obtain additional capital, the Company will be required to reduce the scope of its business development activities or cease operations. The Company continues to explore obtaining additional capital financing and the Company is closely monitoring its cash balances, cash needs, and expense levels.

Management’s strategic plans include the following:

● Continuing to advance commercialization of the Company’s principal product, BAM-FX™® in both domestic and international markets; ● Pursuing additional capital raising opportunities; ● Continuing to explore and execute prospective partnering or distribution opportunities; and ● Identifying unique market opportunities that represent potential positive cash flow.

5● Pursuing additional capital raising opportunities;

● Continuing to explore and execute prospective partnering or distribution opportunities; and

● Identifying unique market opportunities that represent potential positive cash flow.

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

~~Interim~~Basis ~~Financial~~of ~~Statements~~Presentation The interim unaudited condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three months ended March 31, 2019 and 2018, our cash flows for the three months ended March 31, 2019 and 2018, and our financial position as of March 31, 2019 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year. Certain information and disclosures normally included in the notes to the annual audited consolidated financial statements have been condensed or omitted from these interim unaudited condensed consolidated financial statements. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the SEC on October 17, 2019. The December 31, 2018 balance sheet is derived from those statements.

The interim unaudited condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three and nine months ended September 30, 2018 and 2017, our cash flows for the nine months ended September 30, 2018 and 2017, and our financial position as of September 30, 2018 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.

Certain information and disclosures normally included in the notes to the annual audited consolidated financial statements have been condensed or omitted from these interim unaudited condensed consolidated financial statements. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the SEC on August 13, 2018. The December 31, 2017 balance sheet is derived from those statements.

Use of Estimates

The ~~preparation~~accompanying ~~of the~~ unaudited condensed consolidated financial statements have been prepared in ~~conformity~~accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the ~~reported~~ amounts reported in the ~~unaudited condensed consolidated~~ financial statements. ~~Actual~~and ~~results~~accompanying ~~could differ from those estimates~~notes. Significant estimates ~~in the accompanying unaudited condensed consolidated financial statements~~ include ~~the~~ allowance for doubtful accounts and other receivables, inventory reserves and classifications, amortization period and recoverability of intangible assets, valuation of beneficial conversion features in convertible debt, valuation of loss contingencies, valuation of derivative liabilities, valuation of stock-based compensation and the valuation allowance on deferred tax assets. Actual results could differ from those estimates.

Segment Reporting

The Company views its operations and manages its business as one reportable segment. As a result, the interim unaudited condensed consolidated financial statements presented within, relate to our principal operating segment. Customers in the United States accounted for 100% of our revenues. ~~Except~~We ~~for $23,202 in inventory shipped to Paraguay for a sale where the revenue has not been recognized, we~~ do not have any ~~other~~ property or equipment outside of the United States.

Principles of Consolidation

The accompanying interim unaudited condensed consolidated financial statements include the accounts of Zero Gravity Solutions, Inc. and its ~~wholly~~majority-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents

For the purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at ~~September~~March 3031, ~~2018~~2019 and December 31, ~~2017~~2018.

Inventory

Inventory is valued on a lower of first in, first out (FIFO) cost or net realizable value. Inventory consisted of:

	September 30,		December 31,
	March 31,		December 31,
	2018		2017
	2019		2018
Raw materials	$	2125,~~904~~252	$	2317,~~562~~610
Finished product		54100,~~024~~649		4585,~~081~~532
Total Inventory	$	75125,~~928~~901	$	68103,~~643~~142

6During the three months ended March 31, 2019, the Company recorded an impairment of inventory of $9,704. During the year ended December 31, 2018 the Company recorded an impairment of inventory of $32,084. These were included in Costs of Sales.

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

September 30, 2018

(Unaudited)

Property and Equipment

Property and equipment is stated at cost, less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred.

Depreciation is computed on a straight-line basis over estimated useful lives. Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

Impairment of Long Lived Assets

The Company accounts for long-lived assets in accordance with the provisions of ~~ASC~~Accounting Standards Codification Topic (“ ASC”) 360-10-35-15 “Impairment or Disposal of Long-Lived Assets.” This guidance requires that long-lived assets and certain identifiable intangibles be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

March 31, 2019

(Unaudited)

Intellectual Property

The Company reviewed its intellectual property for impairment and determined that it had no recoverable value. $10,210 was recorded as impairment cost for the year ended December 31, 2018.

Concentration of Credit Risk

The Company believes that its credit risk exposure is limited. The Company has never suffered a loss due to funds in excess ~~balances~~of FDIC limits and had no funds held in excess of FDIC limits at March 31, 2019.

Fair Value of Financial Instruments

The Company accounts for financial instruments under Financial Accounting Standards Board (“FASB”) ~~Accounting Standards Codification Topic (~~ASC) 820, Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:

	Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities;

	Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

	Level 3 — assets and liabilities whose significant value drivers are unobservable.

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

As the Company'’s common stock is not traded in an active market, the Company estimates the fair value of its common stock (used in its Black Scholes option pricing model) pursuant to ASC 820. This estimation process maximizes the use of observable inputs, including the quoted price of the Company'’s common stock in an inactive market, the price of the Company'’s common stock determined in connection with transactions in the Company'’s common stock, and an income approach to valuation (a discounted cash flow technique that considers the future cash flows).

The carrying amounts of the Company’s accounts receivable and accounts payable approximate fair value due to the relatively short period to maturity for these instruments. The carrying value of the Company’s notes payable approximates fair value due to their short period to maturity and their stated interest rates, combined with historic interest rate levels.

~~Revenue~~Accounting ~~recognition~~for ~~and accounts receivable~~Derivatives

~~Effective~~The ~~January~~Company 1evaluates its convertible instruments, ~~2018~~options, ~~(Date~~warrants or other contracts to determine if those contracts or embedded components of ~~adoption)~~those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, we“Derivatives ~~recognize~~and ~~revenues~~Hedging.” ~~from~~The result of this accounting treatment is that the ~~sale~~fair value of ~~agricultural~~the ~~biotechnology~~derivative ~~products~~is marked-to-market ~~distributors~~each balance sheet date and ~~customers~~recorded ~~pursuant~~as toa liability. In the ~~provisions~~event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of ~~ASC~~operations ~~606~~as other income (expense). Upon conversion of a note where the embedded conversion option has been bifurcated and accounted for as a derivative liability, ~~“Revenue~~the ~~From~~Company ~~Contracts~~records ~~With~~the ~~Customers”~~shares at fair value, relieves all related notes, derivatives, and debt discounts, and recognizes a net gain or loss on extinguishment. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date.

The company has adopted FASB ASU 2017-11, which simplifies the accounting for certain equity-linked financial instruments and embedded features with down round features that reduce the exercise price when the pricing of a future round of financing is lower. This allows the company to treat such instruments or their embedded features as equity instead of considering them as a derivative. If such a feature is triggered the value is measured pre-trigger and post-trigger. The difference in these two measurements is treated as a dividend, reducing income. The value recognized as a dividend is not subsequently remeasured, but in instances where the feature is triggered multiple times each instance is recognized.

Advertising

The Company conducts advertising for the promotion of its products and services. In accordance with ASC 720-35, “Advertising Costs,” advertising costs are charged to operations when incurred. During the three months ended March 31, 2019 and 2018, such amounts aggregated $36,110 and $1,897, respectively.

Accounting for Leases

In March 2016, the FASB issued ASU No. 2016-02, Leases. The main difference between the provisions of ASU No. 2016-02 and previous GAAP is the recognition of right-of-use assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. ASU No. 2016-02 retains a distinction between finance leases and operating leases, and the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize right-of-use assets and lease liabilities. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This ASU is effective for public business entities in fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted as of the beginning of any interim or annual reporting period. The Company's adoption January 1, 2019, did not have a material impact on the consolidated financial statements.

Legal Expenses

All legal costs are charged to expense as incurred.

Convertible Notes with Fixed Rate Conversion Options

The Company may enter into convertible notes, some of which may contain fixed rate conversion features, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company measures the fair value of the notes at the time of issuance, which is the result of the share price discount at the time of conversion and records the premium to interest expense on the note issuance date.

Debt Issue Cost

Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized over the life of the underlying debt instrument.

Revenue Recognition and Accounts Receivable:

Effective January 1, 2018 (date of adoption), we recognize revenues from the sale of agricultural biotechnology products to distributors and customers pursuant to the provisions of ASC 606, “Revenue From Contracts With Customers”.

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

March 31, 2019

(Unaudited)

We recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The core principle of this Topic is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. Revenue is recognized in accordance with the core principle by applying the following five steps: 1) identify the contracts with a customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to the performance obligations; and 5) recognize revenue when (or as) we satisfy a performance obligation.

Revenues for agricultural chemical products are recognized when title to the products is transferred which may be upon shipment to the customer or receipt by the customer of the product. This satisfies the performance obligation on which we earn the transaction price. There was no cumulative effect of adopting ASC 606. Amounts billed to customers for shipping and handling fees are included in net sales, and costs incurred by the company for the delivery of invoiced goods are classified as cost of goods sold in our Statements of Operations.

The Company determined that no reserve for estimated product returns and allowances was necessary during the ~~nine~~three months ended ~~September~~March 3031, ~~2018~~2019 and ~~2017~~2018. Determination of the reserve for estimated product returns and allowances is based on management's analyses and judgments regarding certain conditions. Should future changes in conditions prove management's conclusions and judgments on previous analyses to be incorrect, revenue recognized for any reporting period could be materially affected.

The Company did not have accounts receivable outstanding at March 31, 2019. At ~~September~~December 3031, 2018, ~~three~~two customers accounted for 100% of total accounts receivable, ~~each~~ representing 5978.61%, ~~22.5%,~~ and 1721.9%, respectively. During the three months ended ~~September~~March 3031, ~~2018~~2019, one customer accounted for ~~75.2~~97% of net sales. During the ~~nine~~period ~~months~~ ended ~~September~~March 3031, 2018, two customers accounted for ~~69.9~~100% of net sales ~~each representing~~, 5075.~~3% and 19.6%, respectively. During the three months ended September 30, 2017, two customers accounted for 94.~~0% ~~of net sales, each representing 79.1%,~~ and 1425.~~9%, respectively. During the nine months ended September 30, 2017 three customers accounted for 69.5% of net sales, each of these customers represented 33.6%, 22.9% and 13.~~0%, respectively.

AtThe ~~December~~Company ~~31,~~extends ~~2017,~~credit ~~three~~to customers ~~accounted~~generally without requiring collateral. The Company monitors its exposure for ~~100%~~credit oflosses ~~total~~and maintains allowances for anticipated losses. The Company records an allowance for doubtful accounts when it is probable that the accounts receivable balance will not be collected. ~~Each~~When estimating the allowance, the Company takes into consideration such factors as its day-to-day knowledge of ~~these~~the ~~three~~financial ~~customers~~position ~~represented~~of ~~46.5%~~specific clients, ~~34.9%~~and the industry and 18size of its clients.6% The bad debt expense for the three months ended March 31, 2019 and 2018 was $342 and $4,060, respectively.

The Company extends credit to customers generally without requiring collateral. The Company monitors its exposure for credit losses and maintains allowances for anticipated losses. The Company records an allowance for doubtful accounts when it is probable that the accounts receivable balance will not be collected. When estimating the allowance, the Company takes into consideration such factors as its day-to-day knowledge of the financial position of specific clients, and the industry and size of its clients. The allowance for doubtful accounts as of September 30, 2018 and December 31, 2017 was $0 and $32,663, respectively.10

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

Cost of ~~sales~~Sales

Cost of sales is comprised of material costs, invoiced shipping costs and royalty expense.

Warrants

The Company recognizes the cost of warrants issued with debt as debt discount in the ~~unaudited condensed~~ consolidated financial statements which is recorded at the warrants relative fair value which is measured based on the grant date fair value of the award. The Company estimates the fair value of each warrant at the grant date by using the Black-Scholes option pricing model.

Stock ~~based~~Based ~~compensation~~Compensation

The Company recognizes the cost of employee services received in exchange for an award of equity instruments in the ~~unaudited condensed~~ consolidated financial statements which is measured based on the grant date fair value of the award. Stock based compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (generally the vesting period). The Company estimates the fair value of each stock award at the grant date by using the Black-Scholes option pricing model using the simplified method to determine the term.

Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, or in the period of grant for awards that vest immediately and have no future service condition. The expense resulting from employee and share-based payments is recorded in general and administrative expense in ~~2018~~the three months ended March 31, 2019 and ~~2017~~2018.

The Company also grants share-based compensation awards to non-employees for service provided to the Company. The Company measures and recognizes the fair value of such transactions based on the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.

In June 2018, the FASB issued ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” ASU No 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. This guidance is applicable to the Company’s fiscal year beginning January 1, 2019. The implementation did not have a material effect on its consolidated financial statements.

Loss per Share

Loss per share is calculated by dividing the Company’s net loss by the weighted average number of common shares outstanding during the period. Diluted earnings loss per share is calculated by dividing the Company’s net income (loss) by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity instruments. The effect of the inclusion of the dilutive shares would have resulted in a decrease in loss per share. Accordingly, the weighted average shares outstanding have not been adjusted for dilutive shares. Outstanding warrants, stock options and convertible debt are not considered in the calculation as the impact of the potential common shares (15totaling 16,~~993~~206,~~998~~685, shares and 1216,~~981~~952,~~000~~975 shares for the ~~nine~~three months ended ~~September~~March 3031, ~~2018~~2019 and ~~2017~~December 31, 2018, respectively), would be to decrease net loss per share.

Research and Development

Research and development costs are charged to expense as incurred.

Warranty Expense

The Company'’s distribution agreements provide for a warranty on products sold. As sales under such distribution agreements have been nominal ~~through~~during ~~2018~~the three months ended March 31, 2019 and ~~2017~~2018, there has been no warranty expense induring ~~2018~~the three months ended March 31, 2019 or ~~2017~~2018. A provision for estimated future warranty costs is to be recorded as cost of sales when products are shipped, and warranty costs are to be based on historical trends in warranty charges as a percentage of gross product shipments. A resulting accrual is to be reviewed regularly, and periodically adjusted to reflect changes in warranty cost estimates.

Income Taxes

The Company accounts for income taxes under the asset and liability method, in which deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is required to the extent any deferred tax assets may not be realizable.

911

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

The Company does not have an accrual for uncertain tax positions as of ~~September~~March 3031, ~~2018~~2019 and December 31, ~~2017~~2018. The Company files corporate income tax returns with the Internal Revenue Service and the ~~States~~states where the Company determines it is required to do so. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. At ~~September~~March 3031, ~~2018~~2019, the Company did not have any accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense recognized during the three ~~or nine~~ months ended ~~September~~March 3031, ~~2018~~2019 or ~~2017~~2018.

Investments

We have an equity investment in a privately held entity ~~as discussed in note 4~~. We account for investments either under the equity method or cost method of accounting depending on our ownership interest and the level of our influence in each joint venture. Investments accounted for under the equity method are recorded based upon the amount of our investment and adjusted each period for our share of the investee's income or loss. Cost method investments are recorded at cost less any impairments. All investments are reviewed for changes in circumstance or the occurrence of events that suggest an other than temporary event where our investment may not be recoverable. All investments were carried at a zero value as of March 31, 2019 (See Note 4).

Reclassifications

Certain amounts in the December 31, 2017 balance sheet have been reclassified from accounts payable, related party to accrued interest, related party to conform to the September 30, 2018 presentation. This reclassification had no effect on current liabilities in either period presented.

Recently Issued Accounting Pronouncements

~~In May 2014, the Financial Accounting Standards Board (“~~FASB”) ~~issued~~ASCs ~~ASC 606, “Revenue from Contracts with Customers”~~ which ~~has~~are ~~been further clarified and amended. The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods~~ or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were are not ~~previously~~effective ~~addressed~~until ~~comprehensively~~after ~~(for~~March ~~example~~31, ~~service~~2019 are ~~revenue~~not ~~and~~expected ~~contract~~to ~~modifications) and clarify guidance for multiple-element arrangements. Entities~~ have ~~the option to apply the new guidance under~~ a ~~retrospective~~significant ~~approach to each prior reporting period presented or a modified retrospective approach with the cumulative~~ effect ofon ~~initially applying~~ the new guidance recognized at the date of initial application within the Statement of Financial Position. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company’s ~~has~~consolidated ~~finalized its assessment of ASC 606 and determined there will be no material effect on our~~ financial position ~~and~~or results of operations. The timing and amount of revenue recognized based on the new standard is consistent with the revenue recognition policy under previous guidance, however, certain additional financial statement disclosures will be required beginning with 2018 reporting, including additional disaggregated view of revenue. We have adopted the new standard effective January 1, 2018, using the modified retrospective transition method.

In March 2016, the FASB issued ASU No. 2016-02, Leases. The main difference between the provisions of ASU No. 2016-02 and previous U.S. GAAP is the recognition of right-of-use assets and lease liabilities by lessees for those leases classified as operating leases under previous U.S. GAAP. ASU No. 2016- 02 retains a distinction between finance leases and operating leases, and the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous U.S. GAAP. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize right-of-use assets and lease liabilities. The accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This ASU is effective for public business entities in fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted as of the beginning of any interim or annual reporting period. The Company has not finalized the analysis to determine the effect of the standard, but believes that it will not have a material impact on the statement of operations.

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

In June 2018, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” ASU No 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. This guidance is applicable to the Company’s fiscal year beginning January 1, 2019. The Company is currently evaluating the potential effects of this guidance on its consolidated financial statements.

In July 2017, the FASB issued Accounting Standards Update No. 2017-11 Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815) (“ASU 2017-11”), which changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. ASU 2017-11 also clarifies existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, ASU 2017-11 requires entities that present earnings per share (EPS) in accordance with ASC Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features in ASC 470-20. For the Company, ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts ASU 2017-11 in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period in either of the following ways: 1. Retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the first fiscal year and interim period(s) in which ASU 2017-11 is effective or 2. Retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented in accordance with the guidance on accounting changes in paragraphs 250-10-45-5 through 45-10. The Company has elected early adoption and the effects of this guidance are reflected in its unaudited condensed consolidated financial statements and there was no cumulative effect adjustment.

On August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No. 33-10532, Disclosure Update and Simplification. The amendments will become effective on November 5, 2018. Among the amendments is the requirement to present the changes in shareholders’ equity in the interim financial statements (either in a separate statement or footnote) in quarterly reports on Form 10-Q. The Company has elected to implement this amendment beginning the first quarter of 2019.

NOTE 2 – PROPERTY AND EQUIPMENT

	September 30, 2018			December 31, 2017
	March 31, 2019			December 31, 2018
Computer equipment	$	13,032		$	1513,~~332~~032
Equipment and furniture		~~136~~138,~~734~~764			~~133~~138,~~940~~764
Leasehold improvements		7,593			7,593
		157,359			156,865
		159,389			159,389
Accumulated Depreciation		(6780,~~514~~197	)		(5273,~~275~~866	)
Property and Equipment - Net	$	8979,~~845~~192		$	~~104~~85,~~590~~523

Depreciation expense for the ~~nine~~period ~~months~~ ended ~~September~~March 3031, ~~2018~~2019 and ~~2017~~2018 was $186,~~770~~331 and $186,~~414~~235, respectively

11NOTE 3 – RELATED PARTY NOTES AND TRANSACTIONS

Convertible Note Payable

The following descriptions of convertible notes and notes payable refer to notes issued to related parties of the Company. For a description of convertible notes and notes payable to non-related parties of the Company see Note 5.

Convertible Notes Payable to Related Parties

Date of Note	Face Value		Debt Discount		Debt Discount Accretion		Carrying Value

July 2015	$	500,000	$	-	$	-	$	500,000
June 2018	$	1,000,000	$	444,416	$	167,417	$	723,001
July 2018	$	250,000	$	111,113	$	41,401	$	180,288
July 2018	$	250,000	$	111,109	$	38,964	$	177,855
December 2018	$	100,000	$	-	$	-	$	100,000
February 2019	$	325,000	$	-	$	-	$	325,000
March 2019	$	100,000	$	-	$	-	$	100,000
	$	2,525,000	$	666,638	$	247,782	$	2,106,144
Convertible Notes Payable - Current	$	925,000	$	-	$	-	$	925,000
Convertible Notes Payable - Long Term	$	1,600,000	$	666,638	$	247,782	$	1,181,144

All of the above notes were converted into new loans with the Series A and Series B offerings in the second quarter 2019.

In July 2015, a member of the Company’s Board of Directors advanced the Company $500,000 under a note payable for working capital purposes. The unsecured note payable bears interest at 8.5% per annum, is payable quarterly, and was originally due in July 2016. In connection with the note, the Company issued warrants to purchase 350,000 shares of the Company’s common stock at an exercise price of $3.00 per share. The Company calculated the fair value of the warrants at $416,618 utilizing the Black-Scholes Model with the following assumptions: expected dividends of 0%, volatility of 184.2%, risk free interest rate of 1.66% and expected life of 5 years. The relative fair value of the warrants was recorded resulting in a debt discount of $227,258 upon execution of the agreement. In July 2016, the maturity date of the note was extended to July 2017, and a conversion feature was added. The conversion feature allows the holder to convert the debt into common shares at his option at a conversion price of $1.25 per share (400,000 shares). The addition of the conversion feature represented a substantial modification to the debt instrument but the modification was determined to not be material. During 2017, the maturity date of the note was extended to July 2018 and then extended again in 2018 to July 2019. The note is included in the current liabilities section of the consolidated balance sheets. This note plus the accrued and unpaid interest was subsequently converted into Series A and B Notes. (See Note 7).

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

~~NOTE~~On June 29, 2018, in connection with its June 2018 Offering (as defined in Note 5), the Company received $1,000,000 from an affiliate of a board member, and in exchange the Company issued (a) an unsecured convertible promissory note dated June 29, 2018, and (b) a two-year warrant dated June 29, 2018 to purchase up to 1,000,000 shares of the Company’s common stock. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly in cash. The note is payable in full plus all unpaid interest thereon, by June 28, 2020. The conversion feature allows the holder to convert the debt into common shares at his option at a conversion price of the lower of $3.00 per share or the Company's current offering price. Prepayment of all unpaid principal and interest –may ~~RELATED~~be ~~PARTY~~made ~~TRANSACTIONS~~by the Company prior to the maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest, based on the full principal amount. The warrant is exercisable within 2 years of issuance into shares of the Company’s common stock, at $1.00 per share. The relative fair value of the warrant recorded resulted in debt discount of $414,416 upon execution. The Company also incurred $30,000 of lender fees which was recorded as debt discount. For the three months ended March 31, 2019, accretion of the debt discount was $54,791, included in other expenses on the statements of operations. This note plus the accrued and unpaid interest was subsequently converted into Series A and B Notes. (See Note 7).

~~The~~On ~~following~~July ~~descriptions~~2, of2018, in connection with its June 2018 Offering (as defined in Note 5), the Company received $250,000 from a board member, and in exchange the Company issued (a) an unsecured convertible ~~notes~~promissory note dated July 2, 2018, and ~~notes~~(b) ~~payable~~a ~~refer~~two-year towarrant ~~notes~~dated ~~issued~~July 2, 2018 to ~~related~~purchase ~~parties~~up to 250,000 shares of the Company’s common stock. ~~For~~The note bears interest at the rate of ten percent (10%) per annum, payable quarterly in cash. This note was subsequently converted into Series A and B Notes (see Note 7). The conversion feature allows the holder to convert the debt into common shares at his option at a ~~description~~conversion price of ~~convertible~~the ~~notes~~lower of $3.00 per share or the Company's current offering price. Prepayment of all unpaid principal and ~~notes~~interest may ~~payable~~be made by the Company prior to ~~non-related~~the ~~parties~~maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest, based on the full principal amount. The warrant is exercisable within 2 years of issuance into shares of the Company’s ~~see~~common stock, at $1.00 per share. The relative fair value of the warrant recorded resulted in debt discount of $103,613 upon execution. The Company also incurred $7,500 of lender fees which was recorded as debt discount. For the three months ended March 31, 2019, accretion of the debt discount was $13,699, included in other expenses on the statements of operations. This note plus the accrued and unpaid interest was subsequently converted into Series A and B Notes. (See Note 57).

~~Convertible~~On July 19, 2018, in connection with its June 2018 Offering, (as defined in Note 5), the Company received $250,000, from a member of our Board of Directors, and in exchange the Company issued (a) an unsecured convertible promissory note dated July 19, 2018, and (b) a two-year warrant dated July 19, 2018 to purchase up to 250,000 shares of the Company’s common stock. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly in cash. This note was subsequently converted into Series A and B Notes ~~Payable~~(see Note 7). The conversion feature allows the holder to ~~Related~~convert ~~Parties~~the debt into common shares at his option at a conversion price of the lower of $3 per share or the Company's current offering price. Prepayment of all unpaid principal and interest may be made by the Company prior to the maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest, based on the full principal amount. The warrant is exercisable within 2 years of issuance into shares of the Company’s common stock, at $1.00 per share. The relative fair value of the warrant recorded resulted in debt discount of $103,609 upon execution. The Company also incurred $7,500 of lender fees. For the three months ended March 31, 2019, accretion of the debt discount was $14,003, included in other expenses on the statements of operations. This note plus the accrued and unpaid interest was subsequently converted into Series A and B Notes. (See Note 7).

Date of Note	Face Value		Debt Discount		Debt Discount Accretion		Carrying Value
July 2015	$	500,000	$	-	$	-	$	500,000
June 2018	$	1,000,000	$	444,416	$	56,617	$	612,201
July 2018	$	250,000	$	111,113	$	13,699	$	152,586
July 2018	$	250,000	$	111,109	$	11,111	$	150,002
	$	2,000,000	$	666,638	$	81,427	$	1,414,789
Convertible Notes Payable - Current	$	500,000	$	-	$	-	$	500,000
Convertible Notes Payable - Long Term	$	1,500,000	$	666,638	$	81,427	$	914,789

On December 21, 2018, the Company received $100,000 from an affiliate of a member of our Board of Directors, and in exchange the Company issued an unsecured convertible promissory note dated December 21, 2018. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly in cash. The note is payable in full plus all unpaid interest thereon, by December 20, 2020. Prepayment of all unpaid principal and interest may be made by the Company prior to the maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest, based on the full principal amount. This note plus the accrued and unpaid interest was subsequently converted into Series A and B Notes. (See Note 7).

InOn ~~July~~February ~~2015~~8, a2019 ~~member~~and ofMarch ~~the~~22, ~~Company’s~~2019, ~~Board of Directors advanced~~ the Company received $~~500~~325,000 ~~under~~and ~~a note payable for working capital purposes. The unsecured note payable bears interest at 8.5% per annum~~$100,000, ~~is payable quarterly~~respectively, ~~and~~from ~~was~~an ~~originally~~affiliate ~~due~~of ina ~~July~~board ~~2016~~member. In ~~connection with the note~~exchange, the Company issued ~~warrants to purchase 350,000 shares of the Company’s common stock at~~ an ~~exercise~~unsecured ~~price~~convertible ofpromissory ~~$3 per~~note ~~share.~~dated ~~The~~February ~~Company calculated the fair value of the warrants at $416~~8,~~618~~ ~~utilizing~~2019 ~~the~~and ~~Black-Scholes~~March ~~Model with the following assumptions: expected dividends of 0%~~22, ~~volatility of 184~~2019.~~2%,~~ ~~risk~~Both ~~free~~notes ~~interest~~were ~~rate~~due ofMay 1~~.66%~~, ~~and~~2019 ~~expected life of 5 years. The relative fair value of the debt~~ and ~~warrants was recorded resulting in a debt discount of $227,258 upon execution of the agreement.~~bore Ininterest ~~July 2016, the maturity date of the note was extended to July 2017, and a conversion feature was added. The conversion feature allows the holder to convert the debt into common shares~~ at ~~his option at~~ a ~~conversion~~rate ~~price~~ of ~~$1.25~~twelve ~~per~~percent ~~share~~ (~~400,000 shares~~12%). ~~The~~per ~~addition of the conversion feature represented a substantial modification to the debt instrument but the modification was determined to not be material~~annum. ~~During~~These ~~2017,~~notes ~~$42,500 was~~plus ~~recorded as interest expense and $10,625 was included in payables at December 31, 2017. During 2017,~~ the ~~maturity~~accrued ~~date of the note was extended to July 2018~~ and ~~then~~unpaid ~~extended again in 2018 to July 2019. For the nine months ended September 30, 2018 and 2017, the Company recorded~~ interest ~~expense~~were ofsubsequently ~~$21,250~~converted oninto the ~~note~~Series ~~recorded in accrued interest~~A -and ~~related~~B ~~party~~Notes. ~~The~~ ~~note~~(See isNote ~~included in the current liabilities section of the unaudited consolidated balance sheets.~~7)

On June 29, 2018, in connection with its June 2018 Offering (as defined in Note 5), the Company received $1,000,000 from an affiliate of a board member, and in exchange the Company issued (a) an unsecured convertible promissory note dated June 29, 2018, and (b) a two-year warrant dated June 29, 2018 to purchase up to 1,000,000 shares of the Company’s common stock. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly in cash. The note is payable in full plus all unpaid interest thereon, by June 28, 2020. The conversion feature allows the holder to convert the debt into common shares at his option at a conversion price of the lower of $3 per share or the Company's current offering price. Prepayment of all unpaid principal and interest may be made by the Company prior to the maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest, based on the full principal amount. The warrant is exercisable within 2 years of issuance into shares of the Company’s common stock, at $1.00 per share. The relative fair value of the note and warrant recorded resulted in debt discount of $414,416 upon execution. The Company also incurred $30,000 of lender fees. During the three month and nine months ended September 30, 2018 accretion of debt discount was $56,617, and was included in other expenses on the statements of operations.14

On July 2, 2018, in connection with its June 2018 Offering (as defined in Note 5), the Company received $250,000 from a board member, and in exchange the Company issued (a) an unsecured convertible promissory note dated July 2, 2018, and (b) a two-year warrant dated July 2, 2018 to purchase up to 250,000 shares of the Company’s common stock. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly in cash. The note is payable in full plus all unpaid interest thereon, by July 1, 2020. The conversion feature allows the holder to convert the debt into common shares at his option at a conversion price of the lower of $3 per share or the Company's current offering price. Prepayment of all unpaid principal and interest may be made by the Company prior to the maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest, based on the full principal amount. The warrant is exercisable within 2 years of issuance into shares of the Company’s common stock, at $1.00 per share. The relative fair value of the note and warrant recorded resulted in debt discount of $103,613 upon execution. The Company also incurred $7,500 of lender fees. During the three month and nine months ended September 30, 2018 accretion of debt discount was $13,699, and was included in other expenses on the statements of operations.

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

OnNotes ~~July~~Payable 19, 2018, in connection with its June 2018 Offering (as defined in Note 5), the Company received $250,000 from a board member, and in exchange the Company issued (a) an unsecured convertible promissory note dated July 19, 2018, and (b) a two-year warrant dated July 19, 2018 to ~~purchase~~Related up to 250,000 shares of the Company’s common stock. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly in cash. The note is payable in full plus all unpaid interest thereon, by July 18, 2020. The conversion feature allows the holder to convert the debt into common shares at his option at a conversion price of the lower of $3 per share or the Company's current offering price. Prepayment of all unpaid principal and interest may be made by the Company prior to the maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest, based on the full principal amount. The warrant is exercisable within 2 years of issuance into shares of the Company’s common stock, at $1.00 per share. The relative fair value of the note and warrant recorded resulted in debt discount of $103,609 upon execution. The Company also incurred $7,500 of lender fees. During the three month and nine months ended September 30, 2018 accretion of debt discount was $11,111, and was included in other expenses on the statements of operations.Parties

Notes Payable to Related Parties
Notes payable outstanding at September 30, 2018 consist of the following:
Date of Note	Face Value		Debt Discount		Debt Discount Accretion		Carrying Value
August 2017	$	100,000	$	10,435	$	5,745	$	95,311
September 2017	$	500,000	$	52,166	$	28,227	$	476,061
October 2017	$	500,000	$	50,229	$	23,256	$	473,028
January 2018	$	500,000	$	50,590	$	20,111	$	469,521
March 2018	$	200,000	$	20,281	$	5,695	$	185,414
May 2018	$	300,001	$	30,452	$	5,572	$	275,121
	$	2,100,001	$	214,153	$	88,606	$	1,974,456

Notes payable outstanding at March 31, 2019 consist of the following:

In August 2017, the Company issued an unsecured promissory note to its then in-house corporate counsel in the principal face amount of $100,000. The promissory note bears interest at a rate of 10.0%, per annum, payable quarterly. The promissory note is payable in full plus all unpaid interest by August 2019. In connection with the note, the Company issued five-year warrants to purchase up to 10,000 shares of the Company’s common stock at an exercise price of $3.00 per share. The relative fair value of the debt and warrants recorded resulted in debt discount of $10,435 upon execution of the promissory note. For the three months ended September 30, 2018, accretion of debt discount was $1,314. For the nine months ended September 30, 2018, accretion of the debt discount was $3,907. Accretion of debt discount is included in other expenses on the statements of operations.

Date of Note	Face Value		Debt Discount		Debt Discount Accretion		Carrying Value

August 2017	$	100,000	$	10,435	$	8,349	$	97,914
September 2017	$	500,000	$	52,166	$	37,717	$	485,551
October 2017	$	500,000	$	50,229	$	33,938	$	483,709
January 2018	$	500,000	$	50,590	$	39,657	$	489,067
March 2018	$	200,000	$	20,281	$	10,751	$	190,470
May 2018	$	300,001	$	30,452	$	13,163	$	282,712
Jan 2019	$	100,000	$	-	$	-	$	100,000
	$	2,200,001	$	214,153	$	143,575	$	2,129,423
Notes Payable - Current	$	1,900,000	$	183,701	$	130,412	$	1,846,711
Notes Payable – Long Term	$	300,001	$	30,452	$	13,163	$	282,712

InAll ~~September 2017, the Company issued an unsecured promissory note to a member~~ of ~~its Board of Directors in~~ the ~~principal~~above ~~face~~notes ~~amount~~were ofconverted ~~$500,000. The~~into ~~promissory~~new ~~note~~loans ~~bears interest at a rate of 10.0%, per annum, payable quarterly. The promissory note is payable in full plus all unpaid interest by September 2019. In connection~~ with the ~~note,~~Series ~~the~~A ~~Company issued five-year warrants to purchase up to 50,000 shares of the Company’s common stock at an exercise price of $3.00 per share. The relative fair value of the debt~~ and ~~warrants~~Series ~~recorded~~B ~~resulted~~offerings in ~~debt discount of $52,166 upon execution of~~ the ~~promissory~~second ~~note.~~quarter ~~For the three and nine months ended September 30, 2018, accretion of the debt discount was $6,574 and $19,508 respectively, included in other expenses on the statements of operations~~2019.

In ~~October~~August 2017, the Company issued toan ~~Rio~~unsecured ~~Vista~~promissory ~~Investments,~~note ~~LLC,~~to aits ~~Nevada~~then ~~limited~~in-house ~~liability~~corporate ~~company~~counsel ~~(“Rio Vista”), (i) an unsecured promissory note~~ in the principal face amount of $~~500~~100,000 ~~and (ii) a warrant to purchase up to 50,000 shares of the Company’s common stock~~. The promissory note ~~issued to Rio Vista~~ bears interest at ~~the~~a rate of ~~ten percent (~~10.0%), per annum, ~~such interest being~~ payable ~~by the Company to Rio Vista~~ quarterly ~~in cash~~. The promissory note iswas ~~payable~~paid in full byduring August ~~the Company, plus all unpaid interest, by October 26,~~ 2019. ~~Prepayment~~In ofconnection ~~all~~with ~~unpaid principal and interest may be made by~~ the ~~Company prior to the date of maturity without penalty or premium. Additionally~~note, the Company issued ~~to Rio Vista~~ a five-year warrant to purchase up to 5010,000 shares of the Company’s common stock at an exercise price of $3.00 per share. The relative fair value of the debt and warrants recorded resulted in debt discount of $5010,~~229~~435 upon execution of the promissory note. For the ~~three and nine months~~ period ended ~~September~~March 3031, ~~2018~~2019, accretion of the debt discount was $61,~~330 and $18~~287,~~784,~~ ~~respectively,~~ included in other expenses on the statements of operations. ~~A member of the Company’s Board of Directors is a beneficiary of certain trusts that own Rio Vista.~~

In ~~January 2018~~September 2017, the Company issued an unsecured promissory note to ~~its~~a ~~then~~member ~~in-house~~of ~~corporate~~its ~~counsel~~Board of Directors, in the principal face amount of $~~100~~500,000. The promissory note bears interest at a rate of 10.0%, per annum, payable quarterly. The ~~promissory~~ note ~~was~~is ~~paid~~payable ~~during~~in ~~the~~full ~~three~~plus ~~month~~all ~~period~~unpaid ~~ended~~interest ~~March~~by ~~31,~~September ~~2018~~2019. In connection with the note, the Company issued a five-year ~~warrants~~ warrant to purchase up to 550,000 shares of the Company’s common stock at an exercise price of $3.00 per share. The relative fair value of the debt and warrants recorded resulted in debt discount of $352,~~831~~ 166 upon execution of the note. For the ~~period~~ three months ended March 31, ~~2018~~2019, accretion of the debt discount was $36,~~831~~431, included in other expenses on the statements of operations.

OnIn orOctober ~~about January 17~~2017, ~~2018,~~ the Company ~~received~~issued ~~$500,000~~to ~~from~~Rio anVista ~~accredited~~Investments, ~~investor~~LLC, ~~and~~a inNevada ~~exchange~~limited ~~the~~liability ~~Company~~company ~~issued~~(“Rio toVista”), ~~the investor~~ (ai) an unsecured ~~promissory~~ note ~~dated January 16, 2018, maturing on October 26, 2019,~~ in the principal face amount of $500,000, and (bii) a warrant ~~dated January 18, 2018~~ to purchase up to 50,000 shares of the Company’s common stock. AThe ~~member~~note ofissued ~~the~~to ~~Company’s Board of Directors is a beneficiary of certain trusts that own~~ Rio Vista, ~~the holder of this note and warrant. The note~~ bears interest at the rate of ten percent (10%) per annum, such interest being payable by the Company to ~~the~~Rio ~~holder thereof~~Vista quarterly in cash. The note is payable in full by the Company, plus all unpaid interest ~~thereon~~, by October 26, 2019. Prepayment of all unpaid principal and interest ~~on the note~~ may be made by the Company prior to the ~~maturity~~ date, ~~provided that the holder thereof shall receive a minimum amount~~ of ~~interest~~maturity without ~~equal~~penalty toor ~~one year of interest under such note, based on the full principal amount~~premium. ~~In addition to the foregoing~~Additionally, the Company ~~must~~issued ~~repay the note~~ to Rio Vista ~~within~~a 30five-year ~~days~~warrant ~~of the date the Company possesses an amount of cash equal~~ to ~~the~~purchase ~~outstanding~~up ~~balance of principal and interest due under the note plus an amount reasonably anticipated~~ to be50,000 ~~necessary to operate the Company over the succeeding 6 months. The warrants are exercisable within 5 years of issuance into~~ shares of the Company’s common stock, at an exercise price of $3.00 per share. The relative fair value of the ~~note~~ debt and warrant recorded resulted in debt discount of $3550,~~590~~229 upon execution~~. The~~ ~~Company also incurred $15,000~~ of ~~lender~~the ~~fees.~~promissory note. For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2018~~2019, accretion of the debt discount was $76,~~215 and $20~~193,~~111,~~ ~~respectively,~~ included in other expenses on the statements of operations. Mr. Alex Boies, a member of the Company’s Board of Directors, is a beneficiary of certain trusts that own Rio Vista.

13On or about January 17, 2018, the Company received $500,000 from an accredited investor, and in exchange the Company issued to the investor (a) an unsecured note dated January 16, 2018, maturing on October 26, 2019, in the principal face amount of $500,000, and (b) a warrant dated January 18, 2018 to purchase up to 50,000 shares of the Company’s common stock. Mr. Alex Boies, a member of the Company’s Board of Directors, is a beneficiary of certain trusts that own Rio Vista, the holder of this note and warrant. The note bears interest at the rate of ten percent (10%) per annum, such interest being payable by the Company to the holder thereof quarterly in cash. The note is payable in full by the Company, plus all unpaid interest thereon, by October 26, 2019. Prepayment of all unpaid principal and interest on the note may be made by the Company prior to the date of maturity, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest under such note, based on the full principal amount. In addition to the foregoing, the Company must repay the note to Rio Vista within 30 days of the date the Company possesses an amount of cash equal to the outstanding balance of principal and interest due under the note plus an amount reasonably anticipated to be necessary to operate the Company over the succeeding 6 months. The warrant is exercisable within 5 years of issuance into shares of the Company’s common stock, at $3.00 per share. The relative fair value of the note and warrant recorded resulted in debt discount of $35,590 upon execution. The Company also incurred $15,000 in lender fees. For the three months ended March 31, 2019, accretion of the debt discount and lender fees was $7,016, included in other expenses on the statements of operations.

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

On or about March 8, 2018, the Company received $200,000 from anMichael ~~accredited~~T. ~~investor~~Smith, ~~and~~ a member of our Board of Directors, and in exchange the Company issued (a) an unsecured promissory note dated March 8, 2018 and (b) a warrant dated March 9, 2018, to purchase up to 20,000 shares of the Company’s common stock. The note bears interest at the rate of ten percent (10%) per annum, such interest being payable by the Company to the holder quarterly in cash. The note is payable in full by the Company, plus all unpaid interest thereon, by March 7, 2020. Prepayment of all unpaid principal due on the note may be made by the Company prior to the note’s maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest due under the note, based on the note’s principal balance as of the origination date. The note contains customary provisions for events of default and acceleration of sums due. The warrant is exercisable within 5 years of issuance into shares of the Company’s common stock, at $3.00 per share. The relative fair value of the note and warrant recorded resulted in debt discount of $14,281 upon execution. The Company also incurred $6,000 ofin lender fees. For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2018~~2019, accretion of the debt discount and lender fees was $2,~~556 and $5~~500,~~695,~~ ~~respectively,~~ included in other expenses on the statements of operations.

On orMay ~~about March 12~~2, 2018, the Company received $~~200~~300,~~000~~ 001 from ~~Boies~~Michael ~~Partners, Inc~~T. ~~(“BPI”)~~Smith, ana ~~accredited~~member ~~investor~~of our Board of Directors, and in exchange the Company issued ~~to BPI~~ (a) an unsecured promissory note dated ~~March~~May 122, 2018, and (b) a warrant dated ~~March~~May 122, 2018 to purchase up to 2030,000 shares of the Company’s common stock. ~~Alex~~The ~~Boies,~~note bears ainterest ~~member~~at ofthe ~~our~~rate ~~Board~~ of ~~Directors,~~ten ~~has~~percent no(10%) ~~financial~~per ~~interest~~annum, payable quarterly in orcash. ~~control~~The ~~over~~note ~~BPI~~is ~~and~~payable ~~does~~in ~~not~~full plus ~~otherwise~~all ~~have~~unpaid ~~any~~interest ~~beneficial~~thereon, ~~ownership~~by inMay ~~any~~1, ~~securities~~2020. ~~owned~~The ~~by BPI,~~note ~~but~~contains ~~BPI is owned by~~ a ~~family~~contingent ~~member~~conversion offeature ~~Alex~~that ~~Boies. The~~allows ~~note bears~~the ~~interest~~value atof the ~~rate~~note ofto ~~ten~~be ~~percent~~converted ~~(10%)~~at $3 per ~~annum,~~share or such lower ~~interest~~price ~~being~~at ~~payable~~which by the Company has issued stock subsequent to ~~the~~May ~~holder~~2, 2018, if any ~~thereof~~part ~~quarterly~~of inthe ~~cash~~principle balance is paid. The ~~note~~intrinsic ~~is payable~~value inof ~~full~~contingent byconversion ~~the~~will ~~Company,~~be ~~plus~~determined ~~all~~and ~~unpaid~~recognized ~~interest~~when ~~thereon,~~the ~~by March~~contingency ~~11, 2020~~occurs. Prepayment of all unpaid principal ~~due~~and ~~on the note~~ interest may be made by the Company prior to the ~~note’s~~ maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest ~~due under the note~~, based on the ~~note’s~~full principal ~~balance as of the origination date~~amount. ~~The note~~ ~~contains customary provisions for events of default and acceleration of sums due.~~ The ~~warrants~~warrant ~~are~~ is exercisable within 5 years of issuance into shares of the Company’s common stock, at $3.00 per share. The relative fair value of the ~~note~~ ~~and~~ warrant recorded resulted in debt discount of $1421,~~279~~452 upon execution. The Company also incurred $69,000 of lender fees. which was recorded as debt discount. For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2018~~2019, accretion of the debt discount and lender fees was $193,~~781 and $20~~754,~~279,~~ ~~respectively,~~ included in other expenses on the statements of operations. This note further provides that within 30 days of receipt of payment of any amount principal outstanding under the note, (the "Conversion Window") the note holder shall have the right to convert any portion of such payment into the Company’s common stock at the lesser of $3.00 per share or the lowest price per share of any sale by the Company of its common stock occurring between the date of the note and the end of the Conversion Window. This note was repaid during the three months ended June 30, 2018.

OnDuring ~~May~~January 22019, ~~2018,~~ the Company received $~~300~~100,~~001~~000 from anMichael ~~accredited~~T. ~~investor~~Smith ~~and~~a member of our Board of Directors, and in exchange the Company issued ~~(a)~~ an unsecured promissory note dated ~~May~~January ~~2, 2018, and (b) a warrant dated May 2, 2018 to purchase up to 30,000 shares of the Company’s common stock~~2019. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly in cash. The note is payable in full plus all unpaid interest thereon, by ~~May~~April 118, ~~2020~~2019. The note contains a contingent conversion feature that allows the value of the note to be converted at $3 per share or such lower price at which the Company has issued stock subsequent to May 2, ~~2018~~2019, if any part of the principle balance is paid. ~~The~~No ~~intrinsic~~beneficial ~~value of contingent~~ conversion ~~will~~feature beexisted ~~determined~~at ~~and recognized when~~ the ~~contingency~~issuance ~~occurs. Prepayment of all unpaid principal and interest may be made by the Company prior to the maturity~~ date, ~~provided that the holder thereof shall receive a minimum amount~~ of ~~interest equal to one year of interest, based on~~ the ~~full principal amount. The warrant is exercisable within 5 years of issuance into shares of the Company’s common stock, at $3.00 per share. The relative fair value of the~~ note ~~and warrant recorded resulted in debt discount of $21,452 upon execution~~. The Company also incurred $9,000 of lender fees. For the three and nine months ended September 30, 2018, accretion of the debt discount and lender fees was $3,841 and $5,572, respectively, included in other expenses on the statements of operations.

1416

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

Royalty Agreement

In 2013, the Company entered into a royalty agreement, which was amended in 2015, with a key employee and principal stockholder of the Company and a ~~current~~former ~~Director~~director of the Company. The agreement ~~has~~had a term of 25 years, ~~requires~~required payments of royalties equal to 5% of gross sales of products derived from certain patents held or licensed by the Company, including the BAM-FX™® product, and also a minimum monthly payment of $2,500 to be offset against future royalty obligations of the Company. In addition certain other costs the Company made that were necessary for the maintenance and protection of the Company’s rights in the underlying patents were applied against future royalty obligations of the Company.

~~Sales~~Included ~~subject~~in toadvance ~~the~~of ~~royalty~~future ~~agreement~~royalties ~~were~~was $~~0 and $4~~203,~~355~~208 ~~for~~in ~~the~~legal ~~three~~fees ~~months~~relating ~~and~~to ~~$33,070~~patent ~~and~~defense. During ~~$65,545 for~~ the ~~nine months~~ year ended ~~September 30, 2018 and 2017, respectively. As of September 30, 2018, and~~ December 31, ~~2017~~2018, ~~$0 and~~this ~~$319,441~~amount ~~of prepaid~~was ~~royalties, respectively, are~~reclassified ~~available~~ to ~~be offset against future royalty obligations. Management recorded~~ an ~~allowance~~intangible ~~for~~asset ~~collectability~~patent ofdefense ~~$6,020~~fees ~~during~~and ~~the~~was ~~three~~determined ~~months~~to ~~ended~~be ~~June 30,~~impaired ~~2018~~ and ~~$129,580~~charged ~~during~~to ~~the nine months ended September 30, 2018 which is included in~~ general and administrative expenses. ~~Sales during the third quarter were not subject to the royalty agreement.~~

~~Included~~Sales insubject ~~advance~~to ofthe ~~future~~royalty ~~royalties~~agreement ~~was~~were $~~203,208~~0 inand ~~legal~~$3,470 ~~fees~~for ~~relating to patent defense. During~~ the ~~nine~~three months ended ~~September~~March 3031, ~~2018,~~2019 ~~this~~and ~~amount was reclassified to an intangible asset patent defense fees~~2018, ~~and was determined to be impaired and charged to general and administrative expenses~~respectively.

On April 29,2019, the royalty agreement was terminated.

Rent

During 2017, the Company entered into a rental agreement for the rent of a laboratory space for $10,000 per month (See Note 4). Raveendran Pottathil, our Chief Technology Officer is an officer of the company that is the primary lessee of the laboratory.

Consulting Agreement

In March 2015, the Company entered into a consulting agreement with a former ~~Director~~director. The agreement had a term of ~~nine~~six months and required payments of $200,000 of which $200,000 was recorded as a component of general and administrative expense in the ~~2015~~ statement of operations for the year ended December 31, 2015. An obligation of $65,000, ~~and~~related ~~$75~~to the consulting agreement,~~000~~ was payable to the former ~~Director~~director and is included in accounts payable at ~~September~~March 3031, ~~2018~~2019 and December 31, ~~2017, respectively~~2018.

NOTE 4 – COMMITMENTS

Lease Commitments

The Company leases its office, building, and laboratory space under short term leases. These leases are renewable either monthly or annually. The Company also has a two-year lease for its production facility and warehouse in Okeechobee, which began September 1, 2016 and expired August 31, 2018. WeThis ~~are~~lease ~~currently~~was ~~finalizing~~extended athrough ~~new~~December ~~two~~31, ~~year~~2019 ~~lease~~and ~~for~~then again through August 31, 2020. We are currently month to month on this ~~facility~~lease. Lease expense was $~~158~~55,~~976~~967 and $7654,~~034~~325 for the ~~periods~~three months ended ~~September~~March 3031, ~~2018~~2019 and ~~2017~~2018, respectively.

License and Business Development Agreement

On February 20, 2018, BAM ~~Agricultural Solutions, Inc. (“BAM”), a wholly-owned subsidiary of the Company,~~ and Pedro Lichtinger Waisman, Isaac Lichtinger Waisman and Victor Lichtinger Waisman (together the “Lichtinger Group”) entered into a License and Business Development Agreement Mexico, effective as of February 13, 2018 (the “Agreement”). Following consummation of the Agreement, the Lichtinger Group formed a company in Mexico, Agro Space Tech SA de CV de RV (“Agro Space”), ~~a Mexican company,~~ to which BAM ~~will~~was ~~receive~~allocated a twenty percent (20%) equity ownership interest. The Lichtinger Group will contribute up to $500,000 in capital into Agro Space, with BAM having no initial capital requirement. If Agro Space requires more than the initial $500,000 capital contribution, BAM will have a right to contribute capital pro rata and maintain its ownership percentage. As of September 30, 2018 Agro Space has been formed, but the Company had not received certificates for its equity ownership, and principal operations have yet to commence. The Company uses the cost method to account for its equity ownership interest due to its minority ownership and lack of management control as the remaining 80% ownership is equally owned by and all operational decisions are made by three individuals, all of whom are related. The recorded cost of the investment was $0 at September 30, 2018.

The Agreement provides Agro Space with the exclusive right to import, package, sell, and distribute BAM’s product lines and promote its brand, as well as other “white label” brands, as they are introduced, in the Mexican markets, and a limited manufacturing right to modify the presentation of BAM’s products and dilute such products, all during the term of the Agreement. BAM will retain the right to all of its intellectual property, including any materials produced in connection with the Agreement and BAM’s products, and Agro Space will have a royalty-free right to reproduce, translate, summarize, or otherwise use such materials for the sole purpose of performing pursuant to the Agreement. The exclusivity of the rights licensed to Agro Space are conditioned upon (i) Agro Space meeting specified revenue targets beginning on the third anniversary following the successful completion of specified local trials through the tenth anniversary thereof; and (ii) the ability for Agro Space to expand the business to target and add a specified number of crops during each of the five (5) years following the successful completion of specified local trials.

In February 2018 in addition to BAM receiving an ownership interest in Agro Space, Zero Gravity Solutions, Inc. ("Company") received $100,000 from the Lichtinger Group following the execution of the Agreement, to purchase shares of the Company pursuant to the Company’s 2016 private offering of shares of its common stock for $3.00 per share (See Note 6). The Agreement further provides that Agro Space will pay to BAM up to $900,000, in the aggregate, upon reaching specified milestones based on completing government/academic trials and revenue hurdles.17

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

In addition to BAM receiving an ownership interest in Agro Space, the Company received $100,000 from the Lichtinger Group following the execution of the Agreement, to purchase shares of the Company’s common stock pursuant to the Company’s 2016 private offering of shares of its common stock for $3.00 per share. The Agreement further provides that Agro Space will pay to BAM up to $900,000, in the aggregate, upon reaching specified milestones based on completing government/academic trials and revenue hurdles.

Research Commitment

In January 2016, the Company entered into a Reimbursable Space Act Agreement (the “SAA”) with the National Aeronautics and Space Administration Ames Research Center (“NASA ARC”). Pursuant to the SAA, NASA ARC will evaluate the Company’s nutrient delivery system for commercial agriculture and NASA applications and the potential development of new agricultural technologies and products. The Company provides funding and reimbursement for the costs incurred by NASA ARC under the SAA, and owns any resulting intellectual property created pursuant to the SAA. The Company paid NASA ARC a total of $373,750 in fiscal 2016, which served as reimbursement for NASA ARC’s estimated expenses to carry out its first-year responsibilities pursuant to the SAA. The SAA remains in effect until the earlier of completion of all obligations contemplated in the SAA or five years from the date of agreement. For the ~~period~~periods ended ~~September~~March 3031, ~~2018~~2019 and ~~2017~~2018, $0there ~~and~~have ~~$29,610,~~been ~~respectively,~~no ~~was~~amounts expensed to research and development expense pursuant to the SAA.

NOTE 5 – CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE

On June 29, 2018, the Company initiated a new private offering of its securities (the “June 2018 Offering”) to certain prospective accredited investors, including certain members of the Board of Directors and/or their respective affiliates (See Note 3), consisting of up to $2,000,000 of 10% secured convertible promissory notes (the “June 2018 Offering Notes”), and two-year warrants to purchase up to 2,000,000 shares of the Company's common stock at an exercise price of $1.00 per share (the “June 2018 Offering Warrants”). The June 2018 Offering terminated on July 31, 2018, and consisted of one or more closings.

The following descriptions of convertible notes and notes payable refer to notes issued to non-related parties of the Company. For a description of convertible notes and notes payable to related parties of the Company, see Note 3.

Convertible Notes Payable to Non-Related Parties
Date of Note	Face Value			~~Debt~~Additional ~~Discount~~Principle		Debt Discount		~~Debt Discount Accretion~~		Debt Discount Accretion		~~Carrying Value~~		Carrying Value
July 2018	$	50,000		$	~~22,231~~	$	22,231	$	~~1,923~~	$	7,552	$	~~29,692~~	$	35,321
July 2018	$	50,000		$	~~22,231~~	$	22,231	$	~~1,923~~	$	7,552	$	~~29,692~~	$	35,321
July 2018	$	25,000		$	~~11,116~~	$	11,116	$	~~873~~	$	3,716	$	~~14,757~~	$	17,600
July 2018	$	250,000		$	~~111,160~~	$	111,160	$	~~9,233~~	$	37,155	$	~~148,073~~	$	175,995
July 2018	$	25,000		$	~~11,115~~	$	11,114	$	~~934~~	$	3,776	$	~~14,819~~	$	17,662
July 2018	$	50,000		$	~~22,232~~	$	22,232	$	~~1,924~~	$	7,553	$	~~29,692~~	$	35,321
July 2018	$	100,000		$	~~44,464~~	$	44,465	$	~~3,659~~	$	14,863	$	~~59,195~~	$	70,398
	$	550,000		$	244,549			$	20,469			$	325,920
December 2018	$	136,000				$	136,000			$	18,682			$	18,682
January 2019	$	94,500	$	10,000		$	94,500			$	23,314			$	33,314
March 2019	$	50,000				$	-			$	-			$	50,000
	$	830,500	$	10,000		$	475,049			$	124,163			$	489,614
Convertible Notes Payable to Non-Related Parties - Current	$	280,500	$	10,000		$	230,500			$	41,996			$	101,996
Convertible Notes Payable to Non-Related Parties - Long-Term	$	550,000	$	-		$	244,549			$	82,167			$	387,618

~~The~~All ~~Company received, in the aggregate, $550,000 from seven other current shareholders and issued June 2018 Offering Notes~~ of ~~$550,000 in exchange therefore, and June 2018 Offering Warrants to purchase, in~~ the aggregate, up to 550,000 shares of the Company’s common stock. The relative fair value of the warrants of $228,049 and offering costs of $16,500 were recorded as debt discounts and are accreted over the term of the note.above ~~Pursuant~~July ~~to the June~~ 2018 Offering, in the aggregate, the Company issued June 2018 Offering Notes having an aggregate principal balance of $2,050,000, and June 2018 Offering two year warrants to purchase up to 2,050,000 shares of the Company’s common stock at $1.00 per share. The notes convert at $3.00 per share, unless the Company issues shares at a subsequent lower price, then the notes convert at that subsequent lower price. See Note 3 for $1,500,000 of June 2018 Offering Notes received by related parties. All June 2018 Offering Warrants issued were ~~accounted~~converted ~~for~~into atnew ~~their~~loans ~~relative fair value of $853,518. These values along~~ with the ~~related~~Series ~~offering~~A ~~costs of $61,500, are recorded as debt discounts~~ and ~~are~~Series ~~accreted~~B ~~over~~offerings in the ~~term~~second ofquarter ~~the note~~2019.

Notes Payable to Non-Related Parties
Date of Note	Face Value		Debt Discount		Debt Discount Accretion		Carrying Value
December 2017	$	200,000	$	18,652	$	7,410	$	188,758
January 2018	$	100,000	$	7,124	$	2,486	$	95,362
	$	300,000	$	25,776	$	9,896	$	284,120

The Company received, in the aggregate, $550,000 from seven current shareholders and issued June 2018 Offering Notes of $550,000 in exchange therefore, and June 2018 Offering Warrants to purchase, in the aggregate, up to 550,000 shares of the Company’s common stock. The relative fair value of the warrants of $228,049 and offering costs of $16,500 were recorded as debt discounts and are accreted over the term of the note. Pursuant to the June 2018 Offering, in the aggregate, the Company issued June 2018 Offering Notes having an aggregate principal balance of $2,050,000, and June 2018 Offering two year warrants to purchase up to 2,050,000 shares of the Company’s common stock exercisable at $1.00 per share. The notes can be converted at the holders’ option at $3.00 per share, unless the Company issues shares at a subsequent lower price, then the notes convert at that subsequent lower price. See Note 3 for $1,500,000 of June 2018 Offering Notes received by related parties. All June 2018 Offering Warrants issued were accounted for at their relative fair value of $853,518. These values along with the related offering costs of $61,500, are recorded as debt discounts and are accreted over the term of the note.

In December 2017, the Company received $200,000 from an investor, and in exchange the Company issued the investor (a) an unsecured promissory note dated December 14, 2017, maturing on December 13, 2019, in the principal face amount of $200,000, and (b) a warrant dated December 18, 2017 to purchase up to 50,000 shares of the Company’s common stock. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly. The note is repayable in full by the Company, plus all unpaid interest thereon, by the maturity date. Prepayment of all unpaid principal and interest on the note may be made by the Company prior to the maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest under the note, based on the full principal amount. The warrants are exercisable within 5 years of issuance into shares of the Company’s common stock, at $3.00 per share. The relative fair value of the debt and warrants recorded resulted in a debt discount of $18,652 upon execution of the promissory note. For the three and nine months ended September 30, 2018, accretion of the debt discount was $2,351 and $7,410, respectively, included in other expenses on the statements of operations.

On or about January 18, 2018, the Company received $100,000 from an accredited investor, and in exchange the Company issued to the investor (a) an unsecured promissory note dated January 19, 2018, maturing on January 18, 2020, in the principal face amount of $100,000, and (b) a warrant dated January 19, 2018 to purchase up to 10,000 shares of the Company’s common stock. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly. The note is repayable in full by the Company, plus all unpaid interest thereon, by the maturity date. Prepayment of all unpaid principal and interest on the note may be made by the Company prior to the maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest under the note, based on the full principal amount. The warrants are exercisable within 5 years of issuance into shares of the Company’s common stock, at $3.00 per share. The relative fair value of the debt and warrants recorded resulted in a debt discount of $7,124 upon execution of the promissory note. For the three and nine months ended September 30, 2018, accretion of the debt discount was $898 and $2,486, respectively, included in other expenses on the statements of operations.

The Company has an outstanding note payable for financing corporate insurance premiums. The original principle value was $223,707. The note carries a rate of interest of 7.5% and is due in November 2018. The note calls for eleven payments of $19,353. The balance at September 30, 2018 was $38,706.

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

On or about December 11, 2018, the Company and an accredited investor, Crossover Capital Fund I, LLC (the “Investor”), entered into a Securities Purchase Agreement, pursuant to which the Investor agreed to invest $125,000 into the Company in exchange for (a) a Convertible Promissory Note of the Company (the “First Note”) having an aggregate principal amount of $136,000 which is convertible into common stock of the Company the Investor shall have the right at any time on or after the issue date to convert all or any part of the outstanding and unpaid principle amount and accrued and unpaid interest of the First Note into fully paid and non-assessable shares of common stock as such, and the conversion price shall be the lesser of $3.00 or 65% multiplied by the market price) and (b) a Common Stock Purchase Warrant to purchase up to 100,000 shares of common stock. The First Note carried an original issue discount of $11,000.

On or about January 14, 2019, the Company and the Investor, entered into a Securities Purchase Agreement, pursuant to which the Investor agreed to invest $82,000 into the Company in exchange for (a) a Convertible Promissory Note of the Company (the “Second Note”) having an aggregate principal amount of $94,500 plus a penalty in the amount of $10,000 for a total of $104,500, which is convertible into common stock, the Investor shall have the right at any time on or after the issue date to convert all or any part of the outstanding and unpaid principle amount and accrued and unpaid interest of this the Second Note into fully paid and non-assessable shares of common stock as such, and the conversion price shall be the lesser of $3.00 or 65% multiplied by the market price) and (b) a Common Stock Purchase Warrant to purchase up to 100,000 shares of common stock. The Second Note carried an original issue discount of $12,500 plus $2,000 of legal fees and the remaining initial discount was $56,002 for the relative fair value of the warrants and $23,998 related to the embedded conversion option derivative liability.

On or about March 2019, a shareholder loaned the Company $50,000 and in exchange was issued 1,000 shares of the Company’s common stock for each week outstanding. The loan was outstanding for just over two weeks so 2,000 shares of the Company's common stock in total were issued and $3,608 was recorded as debt discount and amortization to interest expense as of March 31, 2019.. (See Note 6)

Fair Value Measurements – Derivative Liability – December 2018 and January 2019 convertible notes payable to non-related party –discussed above

Embedded Conversion Option Derivatives

Due to the conversion terms of certain promissory notes, the embedded conversion options met the criteria to be bifurcated and presented as derivative liabilities. The Company calculated the estimated fair values of the liabilities for embedded conversion option derivative instruments at the original note inception dates using the Monte Carlo option pricing model using the share prices of the Company’s stock on the dates of valuation and using the following ranges for volatility, expected term and the risk-free interest rate at each respective valuation date, no dividend has been assumed for any of the periods:

Note Inception Date:	December 11, 2018	March 31, 2019
Volatility:	117%	158%
Expected Term:	9 months	9 Months
Risk Free Interest Rate:	2.56%	2.40%

Note Inception Date:	January 14, 2019	March 31, 2019
Volatility:	130%	142%
Expected Term:	8 months	9 Months
Risk Free Interest Rate:	2.55%	2.44%

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

March 31, 2019

(Unaudited)

Fair value measures

The accounting guidance for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The accounting guidance established a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value. An asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

Assets and liabilities measured at fair value on a recurring and non-recurring basis consisted of the following at March 31, 2019:

Carrying Value

at March 31, 2019

Fair Value Measurements

at March 31, 2019

(Level 1)

(Level 2)

(Level 3)

Embedded Conversion Option Liability

231,000

–

231,000

The following is a summary of activity of Level 3 liabilities for the periods ended March 31, 2019:

Balance at December 31, 2018	$	114,000
Portion of initial valuation recorded as debt discount		89,000
Change in fair value		28,000
Balance at March 31, 2019	$	231,000

Changes in fair value of the embedded conversion option liability are included in other income (expense) in the accompanying consolidated statements of operations.

Notes Payable to Non-Related Parties
Date of Note	Face Value		Debt Discount		Debt Discount Accretion		Carrying Value
December 2017	$	200,000	$	18,652	$	12,060	$	193,408
January 2018	$	100,000	$	7,124	$	4,265	$	97,141
Notes Payable to Non-Related Parties - Current	$	300,000	$	25,776	$	16,325	$	290,549

All of the above notes were converted into new loans with the Series A and Series B offerings in the second quarter 2019 (See Note 7).

In December 2017, the Company received $200,000 from an investor, and in exchange the Company issued the investor (a) an unsecured promissory note dated December 14, 2017, maturing on December 13, 2019, in the principal face amount of $200,000, and (b) a warrant dated December 18, 2017 to purchase up to 50,000 shares of the Company’s common stock. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly. The note is repayable in full by the Company, plus all unpaid interest thereon, by the maturity date. Prepayment of all unpaid principal and interest on the note may be made by the Company prior to the maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest under the note, based on the full principal amount. The warrants are exercisable within 5 years of issuance into shares of the Company’s common stock, at $3.00 per share. The relative fair value of the warrants recorded resulted in a debt discount of $18,652 upon execution of the promissory note. For the three months ended March 31, 2019 and 2018, accretion of debt discount was $2,300, included in other expenses on the statements of operations.

On or about January 18, 2018, the Company received $100,000 from an accredited investor, and in exchange the Company issued to the investor (a) an unsecured promissory note dated January 19, 2018, maturing on January 18, 2020, in the principal face amount of $100,000, and (b) a warrant dated January 19, 2018 to purchase up to 10,000 shares of the Company’s common stock. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly. The note is repayable in full by the Company, plus all unpaid interest thereon, by the maturity date. Prepayment of all unpaid principal and interest on the note may be made by the Company prior to the maturity date, provided that the holder thereof shall receive a minimum amount of interest equal to one year of interest under the note, based on the full principal amount. The warrants are exercisable within 5 years of issuance into shares of the Company’s common stock, at $3.00 per share. The relative fair value of the warrants recorded resulted in a debt discount of $7,124 upon execution of the promissory note. For the three months ended March 31, 2019 and 2018, accretion of the debt discount was $878 and $703, respectively, included in other expenses on the statements of operations. This note plus the accrued and unpaid interest was subsequently converted into a Series A Note. (See Note 7).

The Company has an outstanding note payable for financing corporate insurance premiums. The note carries a rate of interest of 8.75% and is due in November 2019. The note calls for eleven payments of $21,254. The balance at March 31, 2019 and December 31, 2018 was $168,819 and $223,482, respectively.

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

March 31, 2019

(Unaudited)

NOTE 6 – EQUITY

2018 transactions:

Common Stock

~~Private~~Stock ~~placement~~issued ~~offerings~~for services

During ~~2016,~~ the ~~Company~~three ~~commenced~~months ended aMarch ~~private~~31, ~~offering~~2019, ofthe upCompany toissued ~~$10~~45,000~~,000~~ shares of the Company’s ~~securities for $3.00 per share of~~ common stock~~. Pursuant~~ tofor ~~the~~services. ~~2016 offering, during the nine months ended September 30, 2018, the Company sold~~These ~~303,718~~ shares ofwere valued ~~common~~at ~~stock, received gross proceeds of~~ $~~911~~79,~~154,~~950 ~~paid~~based ~~cash~~upon ~~offering~~the ~~costs~~current ~~of $25,680, and issued fully vested, non-forfeitable warrants to purchase up to 7,490 shares of common~~ stock ~~with an exercise~~ price ofat ~~$3.00 per share to~~ the ~~placement~~time ~~agent. These warrants are netted in additional paid in capital as non-cash offering costs~~ of ~~the placement of $5,771~~issue. ~~Effective on June 28, 2018, the Company terminated its 2016 private offering.~~

Stock issued for loan costs

During the three months ended March 31, 2019 the Company issued 2,000 shares of the Company’s common stock as loan costs valued at $3,608.

Warrants

Warrants cashless exercise

During the three months ended March 31, 2019, three former employees exercised 475,500 of their warrants in a cashless exercise resulting in the issuance of 306,195 of the Company’s common shares.

Warrants issued for services

During the ~~nine~~period ~~months~~ ended ~~September~~March 3031, ~~2018~~2019, the Company issued fully vested, non-forfeitable five-year warrants to purchase up to ~~385~~75,000 common shares at an exercise price of $3.00 per common share to ~~employees and~~ consultants for services rendered. The value of those services was $~~296~~57,~~271~~570, which was recorded as general and administrative expense. Additionally, the Company recorded $55,081 of expense related to prior warrants issued for services.

Warrants issued with debt

InOn ~~connection~~or ~~with~~about January 14, 2019, the ~~issuance~~Company ofand aCrossover ~~$100~~Capital Fund I,~~000~~ ~~unsecured~~LLC., ~~promissory~~also ~~note~~referred ~~dated~~to ~~January~~herein 18as the “Investor”, ~~2018~~entered into a Securities Purchase Agreement, pursuant to which the Investor agreed to invest $80,000 into the Company ~~issued~~in exchange for (a) ~~warrant~~a ~~dated~~Convertible ~~January 19~~Promissory Note of the Company also referred herein as the “Second Note”, ~~2018 to~~having ~~purchase~~an upaggregate toprincipal amount of $94,500 plus a penalty of $10,000 ~~shares~~for a total of ~~the~~$104,500. ~~Company’s~~This note is convertible into common stock. ~~The~~and ~~warrants~~the Investor shall ~~are~~have ~~exercisable~~the ~~within~~right 5at ~~years~~any time on or after the issue date to convert all or any part of ~~issuance~~the ~~into~~outstanding ~~shares~~and unpaid principle amount and accrued and unpaid interest of the ~~Company’s~~Second Note into fully paid and non-assessable shares of common stock,. atThe conversion price shall be the lesser of $3.00 ~~per~~or ~~share~~65% multiplied by the market price. (b) ~~The~~a ~~relative~~Common ~~fair~~Stock ~~value~~Purchase Warrant to purchase up to 100,000 shares of ~~the~~common ~~debt~~stock ~~and~~at ~~warrants~~an ~~recorded~~exercise ~~resulted~~price inof ~~debt~~$1.75. The Second Note carried an original issue discount of $714,~~124 upon~~500 ~~execution~~plus there were $2,000 of legal fees and the ~~promissory~~remaining ~~note~~initial discount was $56,002 for the relative fair value of the warrants and $23,998 related to the embedded conversion option derivative liability.

In July 2018, the Company with the issuance, in the aggregate, of $550,000 secured promissory note to seven other current shareholders, issued June 2018 Offering Warrants to purchase, in the aggregate, up to 550,000 shares of the Company’s common stock. The relative fair value of the warrants recorded was $228,049 upon execution of the promissory notes. 21

Warrants issued with debt – related party

In January 2018, the Company issued to its then in-house counsel, in connection with the issuance of an unsecured promissory note in the principal face amount of $100,000, a five-year warrant to purchase up to 5,000 shares of the Company’s common stock at an exercise price of $3.00 per share. The relative fair value of the warrant recorded was $3,831 upon execution of the promissory note.

In January 2018, the Company issued to Rio Vista a five-year warrant to purchase up to 50,000 shares of the Company’s common stock at an exercise price of $3.00 per share in connection with a $500,000 unsecured promissory note. The relative fair value of the debt and warrants recorded resulted in debt discount of $35,590 upon execution of the promissory note.

In March 2018, in connection with issuance of a $200,000 unsecured promissory note to a member of its Board of Directors, the Company issued five-year warrant to purchase up to 20,000 shares of the Company’s common stock at an exercise price of $3.00 per share. The relative fair value of the debt and warrant recorded resulted in debt discount of $14,281 upon execution of the promissory note.

In March 2018, in connection with issuance of a $200,000 unsecured promissory note to an accredited investor, the Company issued five-year warrant to purchase up to 20,000 shares of the Company’s common stock at an exercise price of $3.00 per share. The relative fair value of the debt and warrant recorded resulted in debt discount of $14,279 upon execution of the promissory note.

In May 2018, in connection with issuance of a $300,000 unsecured promissory note to an accredited investor, the Company issued a five-year warrant to purchase up to 30,000 shares of the Company’s common stock at an exercise price of $3.00 per share. The relative fair value of the debt and warrant recorded resulted in debt discount of $21,452 upon execution of the promissory note.

In June 2018, in connection with issuance of a $1,000,000 secured convertible promissory note to an accredited investor made pursuant to the June 2018 Offering, the Company issued a two-year warrant to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share. The relative fair value of the debt and warrant recorded resulted in debt discount of $414,416 upon execution of the promissory note.

In July 2018, in connection with the issuance of two $250,000 secured convertible promissory notes to a member of its Board of Directors made pursuant to the June 2018 Offering, the Company issued two, two-year warrants to purchase up to 250,000 shares of the Company’s common stock for a total of 500,000 shares at an exercise price of $1.00 per share. The relative fair value of the debt and warrant recorded resulted in debt discount of $103,613 and $103,609, respectively upon execution of the promissory note.

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

The following is a summary of the Company’s warrant activity for the ~~nine~~three months ended ~~September~~March 3031, ~~2018~~2019:

	Number of Warrants			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life (in Years)		Aggregate Intrinsic Value
Outstanding - January 1, 2017		9,664,733		$	1.53
Outstanding - January 1, 2019		12,752,685		$	1.86
Granted		1175,~~838,442~~000			2.0129
Exercised		(~~790~~475,~~000~~500	)		2(.0050	)
Cancelled/Forfeited		-(156,000	)		-(.50	)
Outstanding and exercisable - December 31, 2017		10,713,175		$	1.86			2.8	$	2,606,698
Outstanding and exercisable - March 31, 2019		12,296,185		$	1.93			1.9	$	4,029,700
Outstanding - January 1, 2018		10,713,175		$	1.86
Granted		2,577,490			1.14
Exercised		-			-
Cancelled/Forfeited		-			-
Outstanding and exercisable - September 30, 2018		13,290,665		$	1.77			2.1	$	2,687,519

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the estimated fair value of the Company’s stock price on ~~September~~March 3031, ~~2018~~2019 and the exercise price, multiplied by the number of in-the-money warrants) that would have been received by the warrant holders, had all warrant holders been able to, and in fact had, exercised their warrants on ~~September~~March 3031, ~~2018~~2019.

Stock incentive plan options

In November 2015, the Company adopted its 2015 Equity Incentive Plan. The Plan provides stock based compensation to employees, directors and consultants, as more fully described in the Plan. The Company has reserved 4,000,000 shares under the Plan. ~~During the nine months ended September 30, 2018~~ ~~the Company granted options to purchase up to 25~~2,640,000 ~~shares~~are ofstill ~~common~~available ~~stock each, to two employees with an exercise price of $3.00 per share and a term of 10 years. The estimated fair value of $38,441 of the grants~~ for ~~the nine months ended September 30, 2018 was based upon the following management assumptions: For the nine month period ended September 30, 2018, expected dividends of $0, volatility of 101~~issuance.~~7% based on comparative volatility, risk free interest rates of 2.58 - 2.69%, and expected term of the options of 5 years.~~

The Company recognizes compensation expense for stock option grants based on the fair value at the date of grant using the Black-Scholes option pricing model. As the Company does not currently have reliably determined historic stock prices, the Company uses management estimates of stock value. The Company uses historical data, among other factors, to estimate the expected option life and the expected forfeiture rate. The Company estimates expected term considering factors such as historical exercise patterns and the recipients of the options granted. The risk-free rate is based on the United States Treasury Department yield curve in effect at the time of grant for the expected life of the option. The Company assumes an expected dividend yield of zero for all periods. ~~For employee, consultant and director stock based compensation, the Company used management's fair value estimates of $1.21 for the period September 30, 2018.~~

~~Stock option expense for the nine months ended September 30, 2018 was $146,277.~~22

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

The Company has elected to account for forfeitures as they occur.

	Number of Options			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life (in Years)		Aggregate Intrinsic Value
Outstanding - January 1, 2017		2,755,000		$	1.25
Outstanding - January 1, 2019		1,585,000		$	1.70
Granted		~~440,000~~-			~~3.00~~-
Exercised		-			-
Cancelled/Forfeited		(30225,000	)		1(2.2514	)
Outstanding - December 31, 2017		3,165,000		$	1.49			8.5	$	192,850
Outstanding - March 31, 2019		1,360,000		$	1.63			6.6	$	74,550
Exercisable - December 31, 2017		2,750,000		$	1.27			8.2	$	192,850
Exercisable - March 31, 2019		1,335,000		$	1.16			6.5	$	74,550
Outstanding - January 1, 2018		3,165,000		$	1.49
Granted		50,000			3.00
Exercised		-			-
Cancelled/Forfeited		(1,595,000	)		1.34
Outstanding - September 30, 2018		1,620,000		$	1.56			7.9	$	-
Exercisable - September 30, 2018		1,519,375		$	1.30			8.4	$	-

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the estimated fair value of the Company’s stock price on ~~September~~March 3031, ~~2018~~2019 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders, had all option holders been able to, and in fact had, exercised their options on ~~September~~March 3031, ~~2018~~2019.

1923

Table of Contents

ZERO GRAVITY SOLUTIONS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2018~~2019

(Unaudited)

NOTE 7 – SUBSEQUENT EVENTS

~~Subsequent~~May to2019 September 30, 2018, the Company issued fully vested, non-forfeitable five - year warrants to purchase 40,000 common shares at an exercise price of $3.00 per common share to consultants for services rendered, with a fair value of $30,870.Refinancing

InOn ~~November~~or ~~2018~~about May 11, 2019, the Company ~~received~~entered ~~$250,000~~into as an ~~advance~~Exchange onand ~~inventory~~Release ~~purchases~~Agreement ~~from~~(each, an ~~affiliate~~“Exchange Agreement”), with certain holders of athe ~~Member~~Company’s Promissory Notes (each, an “Old Note”), including certain members of the Board of Directors and/or their respective affiliates, pursuant to which, among other things, the holders thereof agreed to exchange all or part of the amounts owed under their Old Notes for new 10% Series A Secured Convertible Promissory Notes (each, a “Series A Note”). The face value of a Series A Note is equal to the principal face amount of an Old Note plus all interest due or accrued under the Old Note through March 31, 2019.

20Furthermore, pursuant to each Exchange Agreement, in connection with any such exchange, the holder of an Old Note may, in their sole discretion, also exchange any warrant that such note holder received in connection with the issuance of the Old Notes for a new warrant to purchase shares of common stock (an “Exchange Warrant”). The new warrants were three-year warrants with a $1.00 exercise price.

Such transactions contemplated by the Exchange Agreements are referred to herein as the “Refinancing”. The Company conducted the Refinancing in reliance upon the exemptions provided in the Securities Act, including Regulation D, Rule 506(b).

Series B Note Offering

Furthermore, the Exchange Agreement provides that the holder of an Old Note may, in their sole discretion, also subscribe for a 12% Series B Secured Convertible Promissory Note (a “Series B Note”), and be allowed to pay up to one-half of the subscription price of the Series B Note with amounts owed under the Old Note.

In accordance with the terms of the Exchange Agreements and in reliance upon the exemptions provided in the Securities Act, including Regulation D, Rule 506(b), the Company initiated a new private offering of its securities to certain prospective accredited investors and holders of Old Notes, and entered into Subscription Agreements (each, a “Subscription Agreement”) with certain of such noteholders, including certain members of the Board of Directors and/or their respective affiliates, pursuant to which, among other things, such noteholders subscribed to purchase Series B Notes and warrants to purchase shares of common stock (each, a “Purchase Warrant”).

The transactions contemplated by the Subscription Agreements are referred to herein as the “Offering”. During May 2019 the aggregate gross proceeds in connections with the Offering were $3,326,427, and proceeds net of commission were $3,226,782. Commissions were paid in connection with the Offering equal to 3% of the principal thereof, totaling $99,645 in the aggregate. The Company intends to use the proceeds from the Offering to fund working capital requirements.

Terms of Notes and Warrants

The Series A Notes and Series B Notes shall collectively be referred to herein as the “Offering Notes”. The Exchange Warrants and Purchase Warrants shall collectively be referred to herein as the “Offering Warrants”. The Offering Notes were made on substantially the same terms, except as noted. The Offering Warrants were made on substantially the same terms, except as noted.

The Series A Notes bear interest at the rate of ten percent (10%) per annum and the Series B Notes bear interest at the rate of twelve percent (12%) per annum, in each case, with such interest being payable by the Company in cash to the holders thereof beginning nine (9) months and fifteen (15) days from the issuance date of such Offering Note with interest payments due on the fifteenth (15th) day of each month thereafter. The Offering Notes shall be repaid in full by the Company, plus all unpaid interest thereon, by thirty-six (36) months from the date of issuance upon the tender of such Offering Note (the “Maturity Date”). Prepayment of all unpaid principal and interest on each such Offering Note may be made by the Company prior to the Maturity Date at any time without penalty or premium upon forty-five (45) days’ prior written notice to the holder of such Offering Note (a “Prepayment Notice”); provided, however, that a holder of a Series B Note may not receive a Prepayment Notice prior to the repayment of the principal and interest owing under any Old Note or Series A Note. The Offering Notes are secured by the assets of the Company and its subsidiaries, with the priority of the Series A Notes being subordinated to that of the Series B Notes. Furthermore, in addition to terms customarily included in such instruments, each holder of an Offering Note is entitled to convert the unpaid principal and interest due and owing under such Offering Note into common stock at any time prior to the earlier of (a) October 1, 2021 or (b) thirty (30) days following a Prepayment Notice. The conversion price under a Series A Note is two dollars ($2.00) per share and the conversion price under a Series B Note is one dollar ($1.00) per share.

Table of Contents

~~Item~~ZERO 2.GRAVITY ~~Management’s~~SOLUTIONS, ~~Discussion~~INC. ~~and~~AND ~~Analysis of Financial Condition and Results of Operations~~SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

March 31, 2019

(Unaudited)

Each (i) Exchange Warrant may be exercised by the holder thereof within three (3) years of issuance into shares of the common stock at an exercise price equal to one dollar ($1.00) per share and (ii) Purchase Warrant may be exercised at any time after issuance and through ninety (90) days after payment in full of the Offering Note at an exercise price equal to (A) one dollar ($1.00) per share if the Purchase Warrant was exercised on or before April 1, 2020, and (B) fifty cents ($0.50) per share if the Purchase Warrant is exercised after April 1, 2020, in each case, by providing to the Company a notice of exercise, payment and surrender of such Offering Warrant. In addition, the Offering Warrants are subject to adjustment upon the occurrence of specified events including, but not limited to, a payment of certain stock dividends, a subdivision or combination of the Company’s outstanding shares of common stock, a reclassification of the common stock, a consolidation or merger of the Company, a sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange affecting the Company. The Company issued fully vested, non-forfeitable warrants to purchase 9,499,600 (3,045,600 Exchange warrants and 6,454,000 Purchase warrants) common shares at an exercise price of $1.00 per common share as part of the Offering.

On April 29, 2019, the Company, entered into a Settlement Agreement with John W. Kennedy, the Company’s former Chief Science Officer and a former member of the Board of Directors, pursuant to which, among other things, the Company assigned USPN 9,816,071, Patent Application No. 15/729,038, Patent Application No. 14/244,084 and International Patent Serial No. PCT/US 15/24045 (collectively, the “Intellectual Property”) to Mr. Kennedy, and Mr. Kennedy agreed to effectuate the transfer of 2,000,000 shares of his common stock of the Company back to the Company (the “Settlement Agreement”). The Intellectual Property relates to technologies that the Company does not intend to pursue. The Settlement Agreement was entered into in order to resolve certain disputes between the Company and Mr. Kennedy concerning various licensing and royalty agreements entered into between the parties covering the Intellectual Property. Pursuant to the Settlement Agreement, the Company and Mr. Kennedy also entered into a Royalty Agreement, providing for, among other things, certain royalty payments to be made to the Company from the gross revenue generated by the Intellectual Property (the “Royalty Agreement”).

Subsequent to March 31, 2019, the Company issued fully vested, non-forfeitable warrants to purchase 79,500 common shares at an exercise price of $2.00 per common share to consultants for services. The estimated fair value of the warrants of approximately $33,879 was based on the following assumptions: expected dividends of 0, volatility of 148.4%, risk-free interest rate of 1.57% - 1.66%, and expected life of the warrants of 1 - 3 years.

Subsequent to March 31, 2019, the Company issued 10 year stock incentive plan options to purchase 100,000 shares of common stock at an exercise price of $3.00 per common share to consultants for services. The estimated fair value of the options of approximately $83,325 was based on the following assumptions: expected dividends of 0, volatility of 148.4%, risk-free interest rate of 1.93% expected life of 5 years.

Subsequent to March 31, 2019, the Company issued 225,000 shares of common stock to consultants for services.

Subsequent to March 31, 2019, certain consultants and former employees exercised warrants in a cashless exercise resulting in the issuance of 146,248 shares of the Company’s common stock.

Subsequent to March 31, 2019, the Company paid $100,000 of related party notes payable and $230,500 of convertible notes payable.

During October 2019 the Company commenced an offering of up to $5,000,000 of 10% Convertible Secured Promissory Notes (the “Notes”) with an initial closing date of December 31, 2019, which was extended for an additional ninety day period. The Notes bear interest at a ten percent (10%) annual rate, payable quarterly in arrears, with the first interest payment due January 15, 2020 and subsequent interest payments due on the fifteenth (15th) day after the end of each calendar quarter thereafter. Interest will be paid in shares of the Company’s common stock at $2.00 per share. The Notes mature 2 years from the closing date. The Notes are convertible into the Company’s common stock at $2.00 per share.

Commencing on the one (1) year anniversary of the issuance of the Notes and ending eleven (11) months thereafter (i.e. one month prior to the Maturity Date), the Company may at any time upon thirty (30) days prior written notice repurchase any or all outstanding Notes without penalty or premium, provided that the holder may convert the Note prior to the end of the 30 day written notice by the Company of its intent to repurchase the Notes, Notice Period.

The Notes are secured by all assets of the Company and its subsidiaries and are subordinate to the security interest granted to holders of the Series A Notes and Series B Notes previously issued by the Company. The Notes are subject to certain covenants and other provisions customary for a transaction of this nature. The Company received $250,000 in proceeds pursuant to the issuance of Notes through December 31, 2019 and incurred no broker fees.

During the first quarter of 2020, the Company furloughed all employees with the exception of three executive officers. During the second quarter of 2020, the Company began to remove certain employees that are key to the Company’s operation, from furlough. The Company incurred payroll liabilities to employees during the first quarter of 2020, of which approximately $200,000 currently remains unpaid.

On May 12, 2020, the Company executed a Payroll Protection Program Term Note, herein referred to as the PPP Note, and received proceeds of $278,800. The PPP Note was issued pursuant to the Coronavirus Aid, Relief, and Economic Securities Act’s, the CARE’s Act, Paycheck Protection Program. All or a portion of the PPP Note is eligible to be forgiven if all eligible employee retention criteria are met and the funds are used for eligible purposes. The Company has not determined an amount eligible for forgiveness. The PPP Note bears interest at 1% based on a 360 day calendar year and is due two years from date of issuance with repayment scheduled monthly beginning in the seventh month following the date of issuance.

Table of Contents

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operation

Overview

Zero Gravity Solutions, Inc., a Nevada corporation (the Company” or “ZGSI”), is aan agricultural based biotechnology company focused on commercializing technology derived from, and designed for, long term spaceflight and planetary colonization with significant applications to agriculture on ~~Earth~~earth. ~~These~~The ~~technologies~~Company’s ~~are~~technology is focused on improving world agriculture by providing valuable solutions to challenges facing humanity , including climate change stress and soil degradation threats to ~~world~~agricultural ~~agriculture~~production and the ~~ability~~increasing inability to feed the world’s rapidly growing population. The Company’s business model is ~~currently~~ focused on ~~one~~its primary ~~business~~technology, ~~generating revenue from agricultural application of~~ BAM-FX™®, which is a cost effective, ~~micro-nutrient~~ionic delivery platform ~~for plants that efficiently delivers minerals~~ and ~~micro-nutrients~~stimulant tofor plants~~. The~~ ~~Company's~~that ~~secondary~~promotes ~~business, Directed Selection™, relates to~~ the ~~production~~delivery ~~and alteration~~ of ~~new~~minerals ~~varieties of novel stem cells with unique~~ and ~~beneficial~~micronutrients ~~characteristics in the prolonged zero/micro gravity environment of the ISS~~systemically. ~~These~~ZGSI ~~novel stem cells, if developed, could be patented for commercial sale to third parties in the agricultural and human regenerative medical markets. The Company~~ is headquartered in Boca Raton, Florida.

Our business activities are ~~separated~~conducted ~~between~~in ~~two~~our ~~primary~~ wholly owned ~~subsidiaries.~~subsidiary, BAM Agricultural Solutions, Inc., (“BAM.”) and our 98% owned subsidiary, Specialty Agricultural Solutions, Inc. (“SASI”) . BAM oversees ~~product~~BAM-FX®’s ~~development,~~commercial introduction and business development through ~~in-field~~product trials and validation ~~tests~~ with crop growers and ~~channel~~distributors ~~partners,~~that ~~product~~have ~~analysis~~established ~~through~~business ~~academic~~networks ~~institutions~~in ~~and~~agricultural ~~NASA~~markets, manufacturing, sales and ~~sale~~agronomy support. In addition, BAM manages the introduction of ~~and~~Gardener’s ~~agronomy~~Choice®, ~~support~~a ready to use product for ~~our~~the ~~BAM-FX™~~home and garden retail markets. SASI, which was incorporated in 2018, supports introducing a commercial product for sale to hydroponic legal cannabis and hemp grow operations. Another subsidiary of the Company, Zero Gravity Life Sciences Inc. (“ZGLS”), iswas ~~expected~~originally toformed ~~be responsible~~ for ~~any future~~ space research projects, life science applications of our technology and conducting research on future BAM ~~Inc.~~ product lines. ZGLS is currently inactive.

The Company is focused on ~~near-term~~ revenue generation through ~~the~~sale ~~introduction~~ of ~~the Company’s first commercial product,~~ BAM-FX™®, toin domestic and international agricultural markets. BAM-FX™® is licensed in and registered for sale as a fertilizer application ~~with~~in ~~forty-five~~all fifty (4550) domestic states and has been approved for import and commercial sales in Chile, Paraguay, Colombia, Brazil and China. The Company is also pursuing import approval through proper governmental officials and agencies to begin commercial sales in ~~Haiti,~~ Philippines and India. Pursuant to a license and business development agreement with Agro Space Tech SA de CV de RV, the Company is providing technical assistance to obtain approval in Mexico. ~~International~~Country specific commercial operations are ~~conducted~~only ~~through~~undertaken with a qualified local business partner having existing in-country ~~established~~business ~~businesses~~relationships. ~~with~~Our ~~which~~business relationship is either a ~~distribution~~license ~~agreement~~or ~~has~~a ~~been~~distribution ~~executed~~agreement.

The Company began domestic product trials on multiple crops in laboratory and academic settings as well as in field applications on grower/end-user crops during 2014 and expanded field applications with those and additional trial participants in subsequent years. ~~Our~~These basic trials ~~show significant~~showed yield, nutritional value and biomass improvements for crops treated. The Company also noted a early indications of a curative response to fungal, bacterial and viral plant diseases. We continue to use ~~validation~~ trials ~~with growers~~ to increase our understanding of the mode of action, application rates and protocols for our product and ~~show~~validate ~~its~~product efficacy. These trials are critical in both market and product development efforts. During the past ~~four~~ five years, the Company increasingly focused on obtaining third-party ~~validated results~~validation, through studies with academic institutions and ~~NASA,~~ in accordance with the Company’s Reimbursable Space Act Agreement ~~("SSA")~~with the National Aeronautics and Space Administration Ames Research Center.

~~During~~ The ~~2016,~~agricultural ~~the~~industry is known to adopt new technology slowly. The Company ~~shifted~~believes ~~domestic~~that ~~business~~slow ~~development~~adoption ~~efforts~~and ~~from~~sales aresults ~~direct~~is due to ~~grower~~the ~~approach~~Company’s inability to ~~developing~~ ~~business~~sufficiently ~~relationships~~differentiate ~~with~~its ~~channel~~product ~~partners~~from other products making similar claims. Additionally, in ~~general,~~a ~~large~~number ~~agricultural~~of row crops, the product ~~distributors~~combined with ~~which~~application ~~the~~costs, ~~Company~~have ~~executed~~not aresulted ~~distribution~~in ~~agreement~~sufficient grower return, especially those crops whose ex-farm pricing is low. ~~Three~~Therefore, ~~distribution~~the ~~agreements~~Company targeted ~~with~~high ~~agricultural~~value ~~product~~crops ~~distributors~~including ingrape, ~~Ohio~~avocado, citrus, berry and ~~California~~hemp ~~were~~and ~~signed~~for specific validation trials during ~~2016~~2019. ~~with~~Based ~~three~~upon ~~additional~~BAM-FX®’s performance in ~~2017~~these trials, ~~expanding~~the ~~into~~Company ~~Pennsylvania.~~expects ~~These~~to focus business development efforts ~~have~~in ~~had~~these ~~limited~~high ~~success~~value ~~domestically~~crops during 2020. During 2017, ~~due~~we developed a ready to ~~limited~~use, ~~third~~home ~~party~~and ~~crop~~garden ~~data~~product, ~~from~~Gardener’s ~~USDA~~Choice® ~~agricultural~~for ~~extension~~retail ormarkets. ~~affiliated~~Independent ~~universities~~third toparties ~~support~~successfully ~~crop~~tested ~~yield~~Gardener’s ~~and~~Choice®, for plant performance ~~predictability~~and consumer safety during 2018. During the fourth quarter of 2017, ~~combined~~the ~~economic~~Company ~~factors~~showcased ~~including~~the product ~~pricing~~concept at a home and ~~risk~~garden ~~aversion~~trade ~~which,~~show inand ~~some~~generated ~~instances~~interest from prospective purchasers. During 2018, ~~did~~through ~~not~~an ~~result~~independent insales ~~sufficient~~team ~~return~~who onintroduced ~~investment~~Gardener’s ~~for~~Choice® ~~channel~~directly ~~partners~~to orAce ~~growers,~~Hardware retailers at their annual trade show and ~~slow~~expanded ~~adoption~~product ~~practices~~introduction ~~found~~to ~~within~~a ~~the~~number ~~agricultural~~of ~~industry~~big box retailers during 2019. We ~~believe slow~~have ~~adoption~~received bypositive ~~channel~~feedback ~~partners~~from isretailers, ~~due~~however tohave ~~their~~secured ~~perceived~~limited ~~commitment~~purchase ~~risk~~commitments ~~based~~during ~~upon~~ the ~~Company’s~~first ~~lack~~quarter or 2019, the time of ~~adequate~~the ~~capital~~year ~~and~~during ~~capital~~which ~~reserves~~retailers topurchase ~~address~~and ~~long~~display ~~term~~product ~~operations~~for the outdoor home and ~~sustainability~~garden season. Gardener’s Choice® has been registered for sale in all domestic states.

~~The~~To ~~Company~~support ~~began~~commercialization ~~to see limited success penetrating domestic~~ and ~~international~~revenue ~~markets~~generation ~~during 2017. Domestically~~efforts, the ~~agronomy~~Company ~~team~~employs ~~conducted~~certified incrop ~~excess~~advisors ~~of one hundred~~ and ~~fifty~~agronomists ~~grower~~for ~~trials~~the totechnical ~~replicate~~requirements ~~positive results from prior years using established product protocols and to refine product protocols on a variety~~ of ~~crops in addition to a number of third party validated trials. We believe a number of growers and channel partners will place~~ product ~~orders~~introduction ~~during~~domestically ~~the fourth quarter of 2018 as BAM-FX™ gains a market foothold in California, Texas, Iowa, Kentucky~~ and ~~Pennsylvania~~internationally. International trials were conducted in China, India, Paraguay, Colombia, Brazil and Chile during 2017. We expect to begin generating revenue in other countries during 2018 as a result of our 2017 trial results and expected positive results from trials in 2018. Our ability to sell in international markets is dependent upon obtaining government approval for commercial import and sale in country and developing and maintaining strong working relationships with distributors in those countries.

We developed a ready to use, home and garden product, Gardener’s Choice, during 2017 for retail markets. Independent third parties successfully tested Gardener’s Choice for plant performance and consumer safety during 2018. During the fourth quarter of 2017, the Company showcased the product concept at a home and garden trade show and generated significant interest from prospective purchasers. During the first quarter of 2018, the Company introduced Gardener’s Choice directly to Ace Hardware retailers at their annual trade show. In October 2018, the Company attended and managed its show booth at the GIE+EXPO, considered to be the industry’s largest showcase for lawn and garden products distributed through home centers, dealers and retailers, in Louisville, Kentucky. The Company generated significant product interest and distributed in excess of one hundred and thirty product order forms to interested parties. We have received positive feedback from retailers and expect to secure purchase commitments for the product during the fourth quarter of 2018.26

We believe we will obtain state registration for sale in all states in the United States, complete promotional material for Gardener’s Choice and have product available for distribution during the fourth quarter of 2018.

To support commercialization and revenue generation efforts, the Company employs certified crop advisors and agronomists for the technical requirements of product introduction domestically and internationally. Reductions in our consulting agronomy staff occurred during the fourth quarter of 2017 due to curtailed operations in Chile, and domestically due to our focus on specific geographies in Texas, California and the Midwest and targeted high value crops.

Table of Contents

The Company continues to develop technical relationships to validate the science incorporated in BAM-FX™® and identify additional commercial markets and licensing opportunities for the product. ~~During~~The ~~the~~majority ~~first quarter~~ of ~~2016,~~this ~~the~~work ~~Company~~was ~~executed~~performed aduring ~~new~~2019 ~~five-year~~by ~~SAA with~~Iowa ~~NASA~~State ~~ARC.~~University ~~The~~on ~~SAA~~new ~~gives~~product ~~the~~formulations, ~~Company~~Colusa ~~access~~County toFarms ~~NASA~~on ~~scientists~~tomato and ~~laboratories,~~Nurture ~~which~~Earth ~~assist~~Research ~~in identifying~~ and ~~documenting~~Development ~~additional~~Pvt. ~~attributes~~Ltd., ofIndia, ~~the~~to ~~Company’s~~identify ~~science~~scientific ~~and~~bio-markers ~~potential~~showing ~~applications~~product inefficacy ~~other~~and ~~segments~~application ~~of agricultural markets~~timing. We ~~continued~~received ~~working~~these ~~with~~results ~~NASA ARC through the second quarter~~ of ~~2017,~~third ~~however have~~party ~~not~~tests ~~funded~~during ~~additional~~the ~~research pursuant to~~first ~~the~~quarter ~~SAA due to lack~~ of ~~adequate resources~~2020. ~~We maintain our relationship with researchers and specialists and expect to continue research when resources are available.~~

The Company manufactures its product in a manufacturing facility in Okeechobee, Florida,. Manufacturing is conducted on an as-needed batch process. The Company continually performs regulatory and process efficiency reviews of manufacturing operations. Our manufacturing plant manager is an experienced biochemical engineer. We have made process improvements and equipment modifications to existing equipment to enhance efficiencies and improve quality control and assurance ~~though~~through ~~September~~March 3031, 2018. Our process improvements more closely align production with a continuous flow production process. The Company expects to engineer, design and build a scale model of a continuous flow process manufacturing facility during 2019 ~~given financial resources are available~~.

We ~~began~~successfully ~~developing~~tested ~~new~~a ~~formulations~~dry ofproduct ~~BAM-FX™~~formulation, towhich ~~address~~maintains ~~nutritional~~the ~~needs~~attributes of ~~plants that are additive to~~ our liquid product’s. ~~current~~Initial ~~zinc~~trials ~~and~~indicate ~~copper~~the dry formulation. ~~New~~has ~~formulations~~the ~~can~~same ~~include~~efficacy ~~boron,~~as ~~manganese~~BAM-FX®, ~~magnesium~~our ~~and~~concentrated ~~iron,~~liquid ~~which~~product. ~~address~~Introduction ~~known~~of ~~plant~~a ~~deficiencies.~~dry Weproduct ~~believe~~will ~~formulations~~reduce transportation ~~can~~and behandling ~~manufactured~~costs toand ~~include~~we ~~all~~believe orwill ~~numerous~~increase ~~combinations~~our ofaddressable ~~these~~markets ~~elements.~~due ~~Certain~~those ~~new~~lower ~~formulations~~transportation ~~have~~related ~~been~~costs We ~~laboratory~~expect ~~tested~~to ~~and~~continue ~~these~~developing new ~~tests~~formulations ~~confirmed~~and ~~the~~our ~~ability~~dry toformulation ~~combine~~in ~~those~~laboratory ~~elements. Testing~~settings, ~~the~~conclude our efficacy oftrials ~~these~~with ~~formulations~~Iowa onState ~~field~~University, ~~crops~~and isdesign ~~expected~~a toproduction ~~begin~~process ~~during~~for the ~~fourth~~dry ~~quarter~~formulated ofproduct ~~2018~~during 2020.

WeAlthough ~~successfully~~we ~~lab~~have ~~tested~~started aand ~~dry~~realized ~~formulation,~~nominal ~~which maintains the attributes of our~~ product sales, ~~during~~we ~~2017.~~anticipate Ifthat ~~the~~in ~~dry formulation produces~~ the ~~same~~near ~~efficacy~~term, asongoing ~~BAM-FX™~~expenses, aincluding ~~concentrated liquid~~ product development, ~~transportation~~ ~~and~~manufacturing ~~handling~~process ~~costs~~improvement, ~~would~~corporate beadministration ~~reduced significantly~~ and wetechnical ~~believe~~product ~~we could increase addressable markets due to lower cost to purchasers. We expect to continue developing new formulations and dry formulations in a laboratory setting~~support, ~~begin~~will tobe ~~perform~~funded ~~efficacy~~primarily ~~trials~~by ~~and~~proceeds ~~design~~from asales ~~scale production process during the fourth quarter~~ of ~~2018,~~our ~~with~~securities ~~the~~and ~~intent~~issuance of ~~adding a number of new specialized products to our current product offering~~debt.

~~Although~~We we have ~~started~~generated ~~and realized~~ nominal ~~product~~revenues ~~sales,~~from weour ~~anticipate~~operations ~~that~~thus infar ~~the~~and ~~near~~believe ~~term,~~with ~~ongoing~~the ~~expenses,~~financial ~~including~~ability ~~product~~to ~~development,~~promote ~~manufacturing~~and ~~process improvement~~market, ~~corporate administration and technical~~ product ~~support,~~sales will beincrease ~~funded~~in 2020 primarily ~~by proceeds~~ from direct sales ofto ~~our~~end ~~securities~~users and ~~debt~~international distributor purchases.

~~During~~We ~~2016~~cannot, ~~the~~however, ~~Company~~guarantee ~~commenced~~we awill ~~private~~be ~~offering~~successful ofin upgenerating tosignificant ~~$10,000,000~~revenue ofin ~~the~~2019 ~~Company’s~~or ~~securities~~2020 ~~consisting~~or ofin ~~3,333,333~~the ~~shares~~execution of ~~common~~our ~~stock~~business ~~for $3~~strategy.00 ~~per~~Our ~~share. Through~~business ~~December~~is ~~31,~~subject ~~2017,~~to ~~proceeds~~risks ~~from~~inherent in the ~~offering~~establishment ~~were~~of ~~$665~~a new business enterprise,~~001~~ ~~with~~including ~~offering~~the ~~costs~~financial ofrisks ~~$53,200.~~associated ~~During~~with the ~~nine~~limited ~~months~~capital ~~ended~~resources ~~September~~currently ~~30,~~available ~~2018,~~to ~~gross~~us ~~proceeds~~for ~~from~~ the ~~offering~~implementation ~~were~~of ~~$911,154 with~~our ~~cash~~business ~~offering~~strategies. ~~costs~~To ofbecome ~~$25,680. Effective~~profitable ~~June~~and 28competitive, ~~2018,~~we ~~the~~must ~~Company~~raise ~~terminated~~additional ~~its~~capital ~~2016~~to ~~private~~execute our ~~offering~~2019 business plan and realize revenues expected.

OnThe ~~June~~ongoing ~~29,~~COVID-19 ~~2018,~~global ~~the~~and ~~Company~~national ~~initiated~~health emergency has caused significant disruption in the ~~June~~international ~~2018~~and ~~Offering~~United ofStates ~~its~~economies ~~securities~~and tofinancial ~~certain~~markets. ~~prospective~~In ~~accredited~~March ~~investors~~2020, ~~including~~the ~~certain~~World ~~members~~Health ofOrganization declared the ~~Board~~COVID-19 outbreak a pandemic. The spread of ~~Directors~~COVID-19 ~~and/or~~has ~~their~~caused ~~respective~~illness, ~~affiliates~~quarantines, ~~consisting~~cancellation of upevents toand $2travel,~~000~~ business and school shutdowns,~~000~~ ofreduction ~~10%~~in ~~secured~~business ~~convertible~~activity ~~promissory~~and ~~notes~~financial transactions, labor shortages, supply chain interruptions and ~~two~~overall economic and financial market instability. The COVID-~~year~~19 ~~warrants~~pandemic tohas ~~purchase~~the uppotential to 2significantly impact the Company’s supply chain,~~000~~ distribution centers,~~000~~ ~~shares~~or logistics and other service providers. During the first quarter of 2020, the Company's ~~common~~furloughed ~~stock~~all atemployees another ~~exercise~~than ~~price~~three ofexecutive $1officers due to the COVID-19 impact on its operation capability.00 ~~per~~Beginning ~~share~~in the second quarter of 2020 the company began to remove certain employees from furlough that are key to ongoing operations. The ~~During~~Company is not able to estimate the ~~nine~~duration ~~months~~of ~~ended~~the ~~September~~pandemic ~~30,~~and ~~2018~~potential impact on the business if disruptions or delays in shipments of product occur. To date, ~~gross~~the ~~proceeds~~Company ~~from~~has experienced product shipment delays due to import restrictions imposed by countries in which the ~~June~~Company ~~2018~~had ~~Offering~~customer ~~were~~purchase $2commitments. In addition,~~050,000,~~ ~~with~~a ~~cash~~severe ~~offering~~prolonged ~~costs~~economic downturn could result in a variety of ~~$61~~risks to the business,~~500.~~ ~~The~~including ~~June~~weakened ~~2018~~demand ~~Offering~~for ~~terminated~~product and a decreased ability to raise additional capital when needed on ~~July~~acceptable 31terms, ~~2018~~if at all. As the situation continues to evolve, ~~and~~the ~~consisted~~Company ofwill ~~one~~continue orto ~~more~~closely ~~closings~~monitor market conditions and respond accordingly.

We have generated nominal revenues from our operations thus far and expect that product sales will increase in 2018 primarily from direct sales to end users, domestic and international channel partners’ distribution efforts, initial revenues from our retail product, Gardner’s Choice and introduction of product into specialty crop markets.27

We cannot, however, guarantee we will be successful in generating significant revenue in 2018 or in the execution of our business strategy. Our business is subject to risks inherent in the establishment of a new business enterprise, including the financial risks associated with the limited capital resources currently available to us for the implementation of our business strategies. To become profitable and competitive, we must raise additional capital to execute our 2018 business plan and realize revenues expected.

Table of Contents

Critical Accounting Policies and Estimates

Our discussion and analysis of our consolidated financial condition and consolidated results of operations are based on our ~~unaudited Condensed~~ Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the amounts reported in our ~~unaudited Condensed~~ Consolidated Financial Statements and accompanying notes. Note 1: Organization and Summary of Significant Accounting Policies in our ~~Condensed~~ Consolidated Financial Statements contains a description of the accounting policies used in the preparation of our consolidated financial statements as well as the consideration of recently issued accounting standards and the estimated impact these standards will have on our consolidated financial statements. We evaluate our estimates on an ongoing basis~~, including those related to revenue recognition and stock-based compensation~~. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Actual amounts could differ significantly from these estimates under different assumptions and conditions.

We define a critical accounting policy or estimate as one that is both important to our consolidated financial condition and consolidated results of operations and requires us to make difficult, subjective or complex judgments or estimates about matters that are uncertain. We believe that the following are the critical accounting policies and estimates used in the preparation of our ~~Condensed~~ Consolidated Financial Statements. In addition, there are other items within our ~~Condensed~~ Consolidated Financial Statements that require estimates but are not deemed critical as defined in this paragraph.

Revenue Recognition

In accordance with ASC 606 we consider apersuasive ~~contract~~evidence ~~with~~of aan ~~customer,~~arrangement to be a signed agreement, a binding contract with the customer or other similar documentation reflecting the terms and conditions under which products are sold. We recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. This recognition generally occurs when the product is shipped to or received by the customer.

Going Concern

We adopted FASB ASU No. 2014-15, Presentation of Financial Statements- Going Concern, during the first quarter of 2016. This standard defines management’s responsibility to evaluate conditions or events as related to uncertainties that raise substantial doubt about our ability to continue as a going concern and to provide related footnote disclosures, as applicable. Management’s estimates and assumptions, used in the evaluation of our ability to meet our obligations as they become due within one year after the date our financial statements are issued, are based on the facts and circumstances at such date and are subject to a material and high level of subjectivity and uncertainty due to the matters themselves being uncertain and subject to modification. The effect of any individual or aggregate changes in the estimates and assumptions, or the facts and circumstances, could be material to the financial statements. We have concluded that there is substantial doubt about our ability to continue as a going concern. The accompanying ~~unaudited condensed~~ consolidated financial statements have been prepared assuming we will continue as a going concern, but do not include any adjustments that might result if we were unable to do so.

Employee Stock-Based Compensation and Share-Based payment to non-employees

We measure employee and non-employee compensation expense for all stock-based awards at fair value on the date of grant and recognize compensation expense over the service period for awards expected to vest.

We use the Black-Scholes option-pricing model to determine the fair value for stock option awards and recognize compensation expense on a straight-line basis over the awards' ’ vesting periods for employees and over the service period for non-employees. Determining the fair value of stock-based awards at the grant date requires judgment. The determination of the grant date fair value of options using an option-pricing model is affected by our estimated common stock fair value as well as assumptions regarding a number of other complex and subjective variables. If any of the assumptions used in the Black-Scholes model changes significantly, stock-based compensation for future awards may differ materially compared with the awards granted previously. In valuing our options, we make assumptions about risk-free interest rates, dividend yields, volatility and weighted-average expected lives, including estimated forfeiture rates, of the options.

2328

Table of Contents

The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, including the expected term and the price volatility of the underlying stock, which determine the fair value of stock-based awards. These assumptions include:

● Risk-free rate. Risk-free interest rates are derived from U.S. Treasury securities as of the option grant date. ● Expected dividend yields. Expected dividend yields are based on our historical dividend payments, which have been zero to date. ● Volatility. Because we have a limited trading history as a public company, we estimate volatility of our share price based on a combination of the published historical volatilities of comparable publicly-traded companies in our vertical markets and the historical volatility of our common stock. ● Expected term. We estimate the weighted-average expected life of the options as 5 years. ● Forfeiture rate. Forfeiture rates are estimated using historical actual forfeiture trends as well as our judgment of future forfeitures. These rates are evaluated at least annually and any change in compensation expense is recognized in the period of the change. The estimation of stock awards that will ultimately vest requires judgment and, to the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative adjustment in the period in which the estimates are revised. We consider many factors when estimating expected forfeitures, including the types of awards and employee class. Actual results, and future changes in estimates, may differ substantially from management's current estimates.

~~The~~● ~~Company~~Expected ~~accounts~~dividend ~~for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees~~yields. ~~Under~~Expected ~~ASC~~dividend ~~505-50,~~yields ~~the~~are ~~Company determines the fair value of the warrants or stock-~~based ~~compensation~~on ~~awards~~our ~~granted~~historical asdividend ~~either the fair value of the consideration received or the fair value of the equity instruments issued~~payments, ~~whichever~~which ishave ~~more~~been ~~reliably~~zero ~~measurable. Any stock options or warrants issued~~ to non-employees are recorded in expense and additional paid-in capital in shareholders' deficit over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each perioddate.

24● Volatility. Because we have a limited trading history as a public company, we estimate volatility of our share price based on a combination of the published historical volatilities of comparable publicly traded companies in our vertical markets and the historical volatility of our common stock.

●

Expected term. We estimate the weighted-average expected life of the options as 5 years.

●

Forfeiture rate. Forfeiture rates are estimated using historical actual forfeiture trends as well as our judgment of future forfeitures. These rates are evaluated at least annually and any change in compensation expense is recognized in the period of the change. The estimation of stock awards that will ultimately vest requires judgment and, to the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative adjustment in the period in which the estimates are revised. We consider many factors when estimating expected forfeitures, including the types of awards and employee class. Actual results, and future changes in estimates, may differ substantially from management's current estimates.

Table of Contents

Results of Operations ~~- For the Three Months Ended September 30, 2018 Compared to the Three Months Ended September 30, 2017~~

For the three months ended	September 30,			September 30,
For the quarter ended	March 31,			March 31,
	2018			2017			$ Change			% Change
	2019			2018			$ Change			% Change
Revenue	$	1144,~~635~~495		$	43,~~355~~470		$	741,~~280~~025			~~167~~1,182.23	%
Cost of Revenue		227,~~476~~313			~~375~~550			226,~~101~~763			~~560~~4,866.30	%
Gross Profit		917,~~159~~182			32,~~980~~920			514,~~179~~262			~~130~~488.14	%
Operating Expenses		1887,~~019,766~~783			1,~~533~~494,~~925~~513			(~~514~~606,~~159~~730	)		(3340.56	)%
Loss from Operations		(1870,~~010,607~~601	)		(1,~~529~~491,~~945~~593	)		~~519~~620,~~338~~992			33(41.96	)%
Other Income / (Expense)		(~~253~~360,~~846~~487	)		(2185,~~446~~084	)		(~~232~~275,~~400~~403	)		(~~1,083~~323.7	)%
Net Loss	$	(1,~~264~~231,~~453~~088	)	$	(1,~~551~~576,~~391~~677	)	$	~~286~~345,~~938~~589			18(21.59	)%
Net Loss per Share - Basic and Diluted	$	(0.03	)	$	(0.04	)	$	0.01			25.0	%
Net Loss per share - Basic and Diluted	$	(0.03	)	$	(0.04	)	$	0.01			(25.0	)%

Revenue for the three months ended ~~September~~March 3031, ~~2018~~2019 was $1144,~~635~~495, an increase of $741,~~280~~025, or ~~167.2~~1,182% over $43,~~355~~470 for the three months ended ~~September~~March 3031, ~~2017~~2018. Revenue is generated from sales to distributors of agricultural products and to growers who have completed trials in multiple crop-growing seasons with positive crop attributes from applying BAM-FX™® to their crops. In general, growers are sensitive to perceived usage risks and any incremental cost associated with new agricultural products, generally continuing their use of traditional lower cost but less effective chelated zinc and copper products. ~~The Company addressed its product pricing in 2017 and adjusted wholesale and retail prices during the first quarter of 2018 to provide growers a more compelling return on their product purchase.~~

~~For~~Cost of Revenue for the three months ended ~~September~~March 3031, ~~2018~~2019, ~~cost of revenue~~ was $227,~~476~~313, an increase of $226,~~101~~763, or 4.866%, over $~~375~~550 ~~reported~~for ~~during~~ the ~~same~~three ~~period~~months inended ~~2017~~March 31, 2018. The increase in cost of revenue is directly related to our increase in revenue for the three ~~period~~months ended ~~September~~March 3031, ~~2018~~2019 over ~~2017~~the three months ended March 31, 2018.

Operating Expenses for the three months ended March 31, 2019 was $887,783, a decrease of $606,730, or 40.6%, over $1,494,513 for the three months ended March 31, 2018. The decrease in operating expenses was primarily due to a decrease in research and development of $83,670, a decrease in loss on royalty advance of $123,560 due to the need for an allowance for questionable collectability, a decrease in impairment costs of $203,208 due to the impairment of intangible assets, a decrease in insurance of $7,995, a decrease in consulting expense of $9,062, a decrease in travel, meals and conference fees of $22,240, a decrease in employee and employee related benefits of $200,958 due a decrease in headcount, and a decrease of $25,188 in non-cash equity compensation paid to consultants, board members and employees. These decreases were primarily offset by an increase in professional fees of $10,448, an increase in advertising and promotion expense of $34,213, and an increase in shipping and manufacturing expenses of $15,195.

~~Table~~Other Expense for the three months ended March 31, 2019 was $360,487, an increase of ~~Contents~~$275,403 or 323.7%, over $85,084 for the three months ended March 31, 2018. The increase in other expense is primarily due to an increase in interest expense of $74,053 and an increase in accretion of debt discount of $173,693 in connection with the Company’s promissory notes.

~~Operating~~Net ~~Expenses~~Loss ~~decreased~~for bythe ~~$514~~three months ended March 31,~~159~~ to2019 was $1,~~019~~231,~~766~~088, ~~for~~a ~~the~~decrease ~~three~~of ~~months~~$345,589, ~~ended~~or ~~September 30~~21.9%, ~~2018~~over ~~compared to~~ $1,~~533~~576,~~925~~677 for the three ~~months~~ month ended ~~September~~March 3031, ~~2017, or 33~~2018.~~5%.~~ The decrease in ~~operating~~net ~~expense~~loss is primarily due to a decrease in operating ~~audit~~expense ~~fees~~for ofthe ~~$40,301,~~period aended ~~decrease~~March ~~in consulting and professional fees of $108~~31,~~649~~ ~~a decrease~~ 2019 of $~~195~~606,~~425 in non-cash equity compensation paid to consultants, board members~~ 730 and ~~employees,~~an ~~and a~~increase ~~decrease~~ in ~~employee~~gross ~~and~~profit ~~employee related benefits and travel expense~~ of $~~166~~14,~~022. These decreases~~262, ~~were primarily~~ offset by ~~and~~ an increase in ~~legal~~other ~~fees~~expense of $20275,~~338~~403.

Other Expense for the three months ended September 30, 2018 increased by $232,400 to $253,846 from $21,446 for the period ended September 30, 2017. The increase in other expense is primarily due to an increase in interest expense of $101,287 and an increase in accretion of debt discount of $130,303 in connection with the Company’s issuance of notes.

Net Loss for the three months ended September 30, 2018 decreased by $286,938 to $1,264,453 from net loss of $1,551,391 for the three months ended September 30, 2017. The decrease in net loss is primarily due to a decrease in operating expenses for the period ended September 30, 2018 of $514,159, offset by an increase in other expense of $232,400.

Results of Operations - For the Nine Months Ended September 30, 2018 Compared to the Nine Months Ended September 30, 2017

For the Nine Months ended	September 30,			September 30,
	2018			2017			$ Change			% Change
Revenue	$	44,705		$	65,545		$	(20,840	)		(31.8	)%
Cost of Revenue		7,754			12,355			(4,601	)		(37.2	)%
Gross Profit		36,951			53,190			(16,239	)		(30.5	)%
Operating Expenses		3,691,813			5,763,147			(2,071,334	)		(35.9	)%
Loss from Operations		(3,654,862	)		(5,709,957	)		2,055,095			36.0	%
Other Income / (Expense)		(460,653	)		(48,161	)		(412,492	)		(856.5	)%
Net Loss	$	(4,115,515	)	$	(5,758,118	)	$	1,642,603			28.5	%
Net Loss per Share - Basic and Diluted	$	(0.10	)	$	(0.15	)	$	0.05			33.3	%

Revenue for the nine months ended September 30, 2018 was $44,705, a decrease of $20,840 or 31.8% over $65,545 for the nine months ended September 30, 2017. The decrease in revenue is primarily due to non-recurring product stocking orders from distributors during the nine months ended September 30 2017 in states with limited grower trials during 2017 and 2018. Revenue is generated from sales to distributors of agricultural products and to growers who have completed trials in multiple crop-growing seasons with positive crop attributes from applying BAM-FX™ to their crops. In general, growers are sensitive to perceived usage risks and any incremental cost associated with new agricultural products, generally continuing their use of traditional lower cost but less effective chelated zinc and copper products. The Company addressed its product pricing in 2017 and adjusted wholesale and retail prices during the first quarter of 2018 to provide growers a more compelling return on their product purchase.

For the nine months ended September 30, 2018, cost of revenue was $7,754, a decrease of $4,601 over $12,355 reported during the same period in 2017. The decrease in cost of revenue is directly related to our decrease in revenue for the period ended September 30, 2018 over 2017.

Table of Contents

Operating Expenses decreased by $2,071,334 to $3,691,813 for the nine months ended September 30, 2018 compared to $5,763,147 for the nine months ended September 30, 2017, or 35.9%. The decrease in operating expense is primarily due to a decrease in audit fees of $137,951, a decrease in non-cash inducement costs of $926,855, a decrease in consulting and professional fees of $426,848, a decrease of $467,213 in non-cash equity compensation paid to consultants, board members and employees, and a decrease in employee and employee related benefits and travel expense of $396,347. These decreases were primarily offset by the increase in impairment costs and write off of royalty advance of $332,788.

Other Expense for the nine months ended September 30, 2018 increased by $412,492 to $460,653 from $48,161 for the nine months ended September 30, 2017. The increase in other expense is primarily due to an increase in interest expense of $208,075 and an increase in accretion of debt discount of $203,065 in connection with the Company's issuance of notes.

Net Loss for the nine months ended September 30, 2018 decreased by $1,642,603 to $4,115,515 from net loss of $5,758,118 for the nine months ended September 30, 2017. The decrease in net loss is primarily due to a decrease in operating expense for the period ended September 30, 2018 of $2,071,334, offset by a decrease in gross profit of $16,239 and an increase in other expense of $412,492.

Use of Cash

Net Cash Used in Operating Activities

Net cash used in operating activities for the ~~nine~~three months ended ~~September~~March 3031, ~~2018~~2019 ~~decreased~~was byapproximately $83643,000, toa decrease of approximately $3414,~~398,~~000, or 48.7%, from $31,~~481~~057,000 for ~~nine~~three months ended ~~September~~March 3031, ~~2017~~2018. The decrease in net cash used in operating activities is primarily due to a decrease in net loss of $1346,~~643,~~000, an increase in ~~impairment~~amortization ~~expense~~of debt acquisition costs of $~~203~~174,000, an increase in ~~reserve~~accounts ~~for~~payable ~~advances~~and onother ~~future~~payables ~~royalties~~ of $~~130~~164,000, an increase in ~~amortization~~accrued ofinterest ~~debt~~related ~~issuance~~party ~~costs~~ of $~~203~~86,000, and aan ~~decrease~~increase in ~~inventory~~prepaid expenses of $4251,000, ~~offset~~due byto anon-cash ~~decrease~~equity inbased ~~accounts~~compensation ~~payable~~expense ~~and other payables~~ of which $~~631~~99,000, was issued with the expense deferred to future periods offset by a decrease in ~~non-cash~~impairment ~~warrant~~loss ~~modification expense~~ of $~~927~~204,000, a decrease in ~~common~~loss ~~stock~~on ~~issued~~advance ~~for~~on ~~services~~future royalties to related parties of $~~150~~124,000, ~~and~~an aincrease ~~decrease~~ in ~~warrants~~deferred ~~issued~~revenue ~~for services~~ of $~~359~~43,000 and a decrease in ~~collections~~equity ofbased ~~accounts~~compensation ~~receivable and prepaid expenses~~ of $~~225~~25,000.

~~Net Cash Used in Investing Activities~~30

~~Net~~Table ~~cash used in investing activities decreased by $11,000 due to a decrease in payment for intellectual property~~ of ~~$7,000 and a decrease in cash paid to purchase equipment $4,000.~~ Contents

Net Cash Provided by Financing Activities

Net cash provided by financing activities ~~increased~~for bythe ~~$377~~three months ended March 31,~~000~~ to2019 was approximately $3602,~~772,~~000, ~~for~~a ~~the~~decrease ~~nine~~of ~~months~~approximately ~~ended~~$485,000, ~~September~~or 3057.5%, ~~2018 from~~ over $31,~~395~~088,000 for the ~~nine~~three months ended ~~September~~March 3031, ~~2017~~2018. The ~~increase~~decrease in net cash provided by financing activities is due primarily to ana ~~increase~~ decrease in proceeds from ~~the~~sale ~~issuance~~ of ~~notes~~common ~~payable~~stock tonet ~~related~~of ~~parties~~payment of offering costs of $2164,~~700,~~000 and a decrease in net proceeds from notes payable related party of $~~750~~900,000 offset by a decrease in ~~proceeds~~payment ~~from~~to ~~exercise~~notes ofpayable ~~warrants~~to by related ~~parties~~ party of $1100,~~185,~~000, an ~~a decrease~~ increase in proceeds from ~~sale~~the ofissuance ~~common stock net~~ of ~~payment~~convertible ofnotes ~~offering~~payable ~~costs~~convertible of $~~954,~~425.000, an increase in ~~payment~~proceeds of notes payable of $~~270~~32,000 and ana ~~increase~~decrease in payment of offering ~~costs~~cost on related party ~~debt~~ of $6427,000.

Liquidity and Capital Resources

The Company expects to incur significant expenses and operating losses for the foreseeable future. Specifically, we estimate that the costs associated with the execution of our ~~2018~~2019 and 2020 business ~~plan~~plans may exceed $350,000 per month. This expense rate is primarily due to: an increase in costs of additional personnel, personnel-related costs and promotional expenses to develop markets for domestic and international sales of our product, BAM-FX™®, our retail product, Gardener’s Choice®, and our cannabis market product introduction; improvements to our manufacturing facility and processes; and, research and product development related expense for expansion of our product line, product improvement and dry formulation. The Company has evaluated its ability to continue as a going concern for the next twelve months from the issue date of the ~~September~~March 3031, ~~2018~~2019 ~~unaudited condensed~~ consolidated financial statements. There is substantial doubt about the Company's ability to continue as a going concern as we do not currently have the funding necessary to support the projected operating costs we expect to ~~need~~ be needed to operate the business through ~~the~~mid-2020. ~~third~~The ~~quarter~~Company is active in its fundraising, and subsequent to March 31, 2019, the Company has raised approximately $3,600,000.

We filed a registration statement on Form 10 with the SEC that became effective in February 2015, which requires us to operate as a fully reporting public company. We expect to continue to incur additional personnel and professional costs associated with operating as a fully reporting public company. Accordingly, we have acknowledged the need to obtain additional funding to operate the Company and have continued to raise funds through a private offering.

2731

Table of Contents

Adequate additional financing may not be realized from a our private offering or otherwise may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. We will need to generate significant revenues to achieve profitability, and we may never do so.

Cash on Hand

As of ~~September~~March 3031, ~~2018~~2019, the Company had a cash balance of approximately $~~382~~3,000 compared to a cash balance of approximately $1444,000 as of December 31, ~~2017~~2018.

Total assets were approximately $~~710~~517,000 and $~~740~~552,000 at ~~September~~March 3031, ~~2018~~2019 and December 31, ~~2017~~2018, respectively. Working capital (deficit) was $(~~420~~4,364,000) and $(12,~~225~~691,000) at ~~September~~March 3031, ~~2018~~2019 and December 31, ~~2017~~2018, respectively. The ~~decrease~~increase in working capital deficit of $~~805~~1,673,000 during the period was primarily due to cash ~~provided~~used byin ~~financing~~operating activities of $3640,~~772,~~000 offset by cash ~~used~~provided inby ~~operating~~financing activities of $3600,~~398,~~000 and reclassification of notes payable to short term. Total stockholders’ deficit increased by $1,~~844~~135,000 to $(36,~~814~~131,000) at ~~September~~March 3031, ~~2018~~2019 from $(15,~~969~~096,000) at December 31, ~~2017~~2018.

Outlook

Required Capital ~~Over~~Going ~~the Next Year~~Forward

Due to the fact that our product, BAM-FX™®, is new in the agricultural markets, it is difficult to accurately predict revenues and cash flow at this time. We ~~will~~required ~~need~~ additional funding to cover ~~2018~~2019 expenses. ~~Subsequent~~and ~~to December 31, 2017 through September 30, 2018,~~ we ~~issued~~will ~~303,718 shares~~need ofadditional ~~common~~funding ~~stock pursuant to our private offering for approximately $911,000~~ in ~~gross proceeds~~2020.

On or about ~~January~~May 1711, ~~2018~~2019, the Company ~~received~~entered ~~$500,000~~into ~~from~~ an ~~accredited~~Exchange ~~investor~~and Release Agreement (each, ~~and~~an in“Exchange ~~exchange~~Agreement”), ~~the~~with ~~Company~~certain ~~issued~~holders toof the ~~investor~~Company’s Promissory Notes (a)each, an ~~unsecured~~“Old ~~promissory~~Note”), ~~note~~including ~~dated~~certain ~~January~~members ~~16,~~of ~~2018,~~the ~~maturing~~Board onof ~~October~~Directors ~~26,~~and/or ~~2019,~~their inrespective ~~the~~affiliates, ~~principal~~pursuant ~~face~~to ~~amount~~which, ofamong ~~$500~~other things,~~000~~ (the ~~“First~~holders ~~Note”),~~thereof ~~and~~agreed ~~(b)~~to aexchange ~~warrant~~all ~~dated~~or ~~January~~part ~~18,~~of ~~2018~~the toamounts ~~purchase~~owed upunder totheir ~~50,000~~Old ~~shares~~Notes offor ~~the~~new ~~Company’s~~10% ~~common~~Series ~~stock~~A ofSecured Convertible Promissory Notes (~~the~~each, a “~~First~~Series ~~Warrant~~A Note”). AThe ~~member~~face value of ~~the~~a ~~Company’s~~Series ~~board~~A ofNote ~~directors~~ is aequal ~~beneficiary~~to ofthe ~~certain~~principal ~~trusts~~face ~~that~~amount ~~own~~of ~~Rio~~an ~~Vista~~Old ~~Investments,~~Note ~~LLC,~~plus ~~the~~all ~~holder~~interest ofdue or accrued under the ~~First~~Old Note ~~and~~through ~~First~~March ~~Warrant~~31, 2019.

~~On or about January 18~~Furthermore, ~~2018,~~pursuant ~~the Company received $100,000 from an accredited investor, and in exchange the Company issued~~ to ~~the~~each ~~investor~~Exchange ~~(a) an unsecured promissory note dated January 19~~Agreement, ~~2018, maturing on January 18, 2020,~~ in ~~the~~connection ~~principal~~with ~~face~~any ~~amount~~such ~~of $100~~exchange,~~000~~ (the ~~“Second~~holder ~~Note”), and (b) a warrant dated January 19, 2018 to purchase up to 10,000 shares~~ of ~~the~~an ~~Company’s~~Old ~~common stock of (the “Second Warrant”). The First~~ Note ~~and Second Note shall collectively be referred to as the “January Notes”~~may, and the First Warrant and Second Warrant shall collectively be referred to as the “January Warrants”. The Notes and Warrants were made on substantially the same terms, except as noted. The January Notes bear interest at the rate of ten percent (10%) per annum, such interest being payable by the Company to the holders thereof quarterly in ~~cash.~~their ~~The~~sole ~~January Notes are payable in full by the Company~~discretion, ~~plus~~also ~~all~~exchange ~~unpaid~~any ~~interest~~warrant ~~thereon, by their respective maturity dates. Prepayment of all unpaid principal and interest on each note may be made by the Company prior to such notes's maturity date, provided~~ that ~~the holder thereof shall receive a minimum amount of interest equal to one year of interest under~~ such note, ~~based~~holder onreceived ~~the~~in ~~full~~connection ~~principal~~with ~~amount. In addition to~~ the ~~foregoing,~~issuance ~~the Company must repay the First Note to Rio Vista Investments, LLC within 30 days~~ of the ~~date~~Old ~~the~~Notes ~~Company~~for ~~possesses~~a annew ~~amount~~warrant ~~of cash equal~~ to ~~the~~purchase outstanding balance of principal and interest due under the Second Note plus an amount reasonably anticipated to be necessary to operate the Company over the succeeding 6 months. The January Warrants are exercisable within 5 years of issuance into shares of ~~the Company’s~~ common stock, at(an ~~$3.00~~“Exchange ~~per share~~Warrant”).

28Such transactions contemplated by the Exchange Agreements are referred to herein as the “Refinancing”. The Company conducted the Refinancing in reliance upon the exemptions provided in the Securities Act, including Regulation D, Rule 506(b).

Furthermore, each Exchange Agreement provides that the holder of an Old Note may, in their sole discretion, also subscribe for a 12% Series B Secured Convertible Promissory Note (a “Series B Note”) and be allowed to pay up to one-half of the subscription price of the Series B Note with amounts owed under the Old Note.

The transactions contemplated by the Subscription Agreements are referred to herein as the “Offering”. Aggregate gross proceeds in connections with the Offering were $3,326,427, and proceeds net of commission were $3,226,782. Commissions were paid in connection with the Offering equal to 3% of the principal thereof, totaling $99,645 in the aggregate. The Company intends to use the proceeds from the Offering to fund working capital requirements.

Table of Contents

OnThe orSeries ~~about~~A ~~March~~Notes 8bear interest at the rate of ten percent (10%) per annum and the Series B Notes bear interest at the rate of twelve percent (12%) per annum, ~~2018~~in each case, with such interest being payable by the Company ~~received~~in ~~$200,000~~cash ~~from~~to anthe ~~accredited~~holders ~~investor~~thereof beginning nine (9) months and ~~member~~fifteen (15) days from the issuance date of ~~our~~such ~~Board~~Offering Note with interest payments due on the fifteenth (15th) day of ~~Directors,~~each ~~and~~month thereafter. The Offering Notes shall be repaid in ~~exchange~~full by the Company, ~~issued~~plus all unpaid interest thereon, by thirty-six (a36) anmonths ~~unsecured~~from ~~promissory~~the ~~note~~date ~~dated~~of ~~March~~issuance 8,upon ~~2018~~the tender of such Offering Note (the “~~Third~~Maturity ~~Note~~Date”),. Prepayment of all unpaid principal and interest on each such Offering Note may be made by the Company prior to the Maturity Date at any time without penalty or premium upon forty-five (b45) days’ prior written notice to the holder of such Offering Note (a ~~warrant~~“Prepayment ~~dated~~Notice”); ~~March~~provided, 9however, ~~2018~~that a holder of a Series B Note may not receive a Prepayment Notice prior to ~~purchase~~the uprepayment of the principal and interest owing under any Old Note or Series A Note. The Offering Notes are secured by the assets of the Company and its subsidiaries, with the priority of the Series A Notes being subordinated to 20that of the Series B Notes. Furthermore,~~000~~ ~~shares~~in additional to terms customarily included in such instruments, each holder of an Offering Note is entitled to convert the ~~Company’s~~unpaid principal and interest due and owing under such Offering Note into common stock at any time prior to the earlier of (a) October 1, 2021 or (b) thirty (30) days following a Prepayment Notice. The conversion price under a Series A Note is two dollars ($2.00) per share and the ~~“Third~~conversion ~~Warrant”~~price under a Series B Note is one dollar ($1.00) per share.

OnEach or(i) ~~about~~Exchange ~~March~~Warrant ~~12,~~may ~~2018,~~be exercised by the ~~Company~~holder ~~received~~thereof ~~$200,000~~within ~~from~~three ~~Boies~~(3) ~~Partners,~~years ~~Inc~~of issuance into shares of the common stock at an exercise price equal to one dollar ($1.00) per share and (~~“BPI”~~ii), anPurchase ~~accredited~~Warrant ~~investor,~~may be exercised at any time after issuance and through ninety (90) days after payment in ~~exchange~~full of the ~~Company~~Offering ~~issued~~Note at an exercise price equal to ~~BPI~~(A) one dollar (a$1.00) anper ~~unsecured~~share ~~promissory~~if ~~note~~the ~~dated~~Purchase ~~March~~Warrant ~~12,~~is ~~2018~~exercised ~~(the~~on ~~“Fourth~~or ~~Note”)~~before April 1, 2020, and (bB) fifty cents ($0.50) per share if the Purchase Warrant was exercised after April 1, 2020, in each case, by providing to the Company a ~~warrant~~notice ~~dated~~of ~~March~~exercise, 12payment and surrender of such Offering Warrant. In addition, ~~2018~~the Offering Warrants are subject to ~~purchase~~adjustment upupon the occurrence of specified events including, but not limited to, 20a payment of certain stock dividends,~~000~~ ~~shares~~a subdivision or combination of the Company’s outstanding shares of common stock, (a reclassification of the ~~“Fourth~~common ~~Warrant”).~~stock, ~~Alex~~a ~~Boies~~consolidation or merger of the Company, a ~~member~~sale or transfer of ~~our~~all ~~Board~~or substantially all of ~~Directors~~the assets of the Company, ~~has~~or noany ~~financial~~compulsory ~~interest~~share inexchange oraffecting ~~control~~the ~~over~~Company. ~~BPI~~The ~~and~~Company ~~does~~issued ~~not~~fully ~~otherwise~~vested, ~~have~~non-forfeitable ~~any~~warrants ~~beneficial~~to ~~ownership~~purchase in9,499,600 common ~~any~~shares ~~securities~~at ~~owned~~an byexercise ~~BPI~~price of $1.00 per share as part of the Offering.

~~The~~Subsequent ~~Third~~to ~~Note~~March ~~and~~31, ~~Fourth~~2019, ~~Note~~the ~~shall~~Company ~~collectively~~issued befully ~~referred~~vested, tonon-forfeitable aswarrants ~~the~~to ~~“March~~purchase ~~Notes”~~79,500 ~~and~~common ~~the~~shares ~~Third~~at ~~Warrant~~an ~~and~~exercise ~~Fourth~~price ~~Warrant~~of ~~shall~~$2.00 ~~collectively~~per becommon ~~referred~~share to asconsultants ~~the~~for ~~“March Warrants”~~services. The ~~Notes~~estimated ~~were~~fair ~~made~~value onof ~~substantially~~the warrants of approximately $33,879 was based on the ~~same~~following ~~terms~~assumptions: expected dividends of 0, ~~except~~volatility asof ~~noted~~148.4%, ~~The~~risk-free ~~Warrants~~interest ~~were~~rate ~~made~~of on1.57% - 1.66%, and expected life of the ~~same~~warrants ~~terms~~of 1 - 3 years.

~~The~~Subsequent ~~March Notes bear interest at the rate of ten percent (10%) per annum, such interest being payable by the Company~~ to ~~the holders thereof quarterly in cash. The~~ March ~~Notes are payable in full by the Company~~31, ~~plus all unpaid interest thereon~~2019, ~~by March 7, 2020 and March 11, 2020, respectively. Prepayment of all unpaid principal due on each Note may be made by~~ the Company ~~prior~~issued ~~to each such Note’s maturity date~~225,000 ~~provided~~shares ~~that the holder thereof shall receive a minimum amount~~ of ~~interest~~common ~~equal~~stock to ~~one~~consultants ~~year of interest due under such Note, based on such Note’s principal balance as of the origination date. The Notes contains customary provisions~~ for ~~events of default and acceleration of sums due~~services.

~~The~~Subsequent ~~Fourth~~to ~~Note~~March ~~further~~31, ~~provides~~2019, ~~that~~certain ~~within~~consultants 30and ~~days~~former ofemployees ~~receipt~~exercised ofwarrants ~~payment~~in ofa ~~any~~cashless ~~amount~~exercise ~~principal~~resulting ~~outstanding~~in ~~under~~ the ~~Fourth~~issuance ~~Note~~of ~~(the “Conversion Window”)~~146,248 ~~the~~shares ~~note holder shall have the right to convert any portion~~ of ~~such payment into~~ the Company’s common stock ~~at the lesser of $3~~.~~00 per share or the lowest price per share of any sale by the Company of its common stock occurring between the date of the Fourth Note and the end of the Conversion Window.~~

~~The~~Subsequent to March ~~Warrants~~31, ~~are~~2019, ~~exercisable~~the ~~within~~Company 5paid ~~years~~$100,000 of ~~issuance~~related ~~into~~party ~~shares~~notes ofpayable ~~the~~and ~~Company’s common stock~~$230,500 atof ~~$3.00~~convertible ~~per~~notes ~~share~~payable.

InDuring ~~May 2018~~October 2019 the Company commenced an offering of up to $5,000,000 inof ~~connection~~10% Convertible Secured Promissory Notes (the “Notes”) with ~~issuance~~an initial closing date of aDecember ~~$300~~31,~~001 unsecured~~ ~~promissory~~2019, ~~note~~which towas extended for an ~~accredited~~additional ~~investor~~ninety day period. The Notes bear interest at a ten percent (10%) annual rate, payable quarterly in arrears, with the ~~Company~~first ~~issued~~interest ~~five-year~~payment ~~warrant~~due January 15, 2020 and subsequent interest payments due on the fifteenth (15th) day after the end of each calendar quarter thereafter. toInterest ~~purchase~~will upbe topaid ~~30,000~~in shares of the Company’s common stock at ~~an exercise price of~~ $32.00 per share. The ~~relative~~Notes ~~fair~~mature ~~value~~2 ofyears from the ~~debt~~closing ~~and~~date. ~~warrant recorded~~The ~~resulted~~Notes inare ~~debt~~convertible ~~discount~~into ofthe ~~$21,452 upon~~Company’s ~~execution~~common ofstock ~~the~~at ~~promissory~~$2.00 ~~note~~per share.

In Commencing ~~June 2018,~~on inthe ~~connection~~one ~~with~~(1) year anniversary of the issuance of athe ~~$1,000,000~~Notes ~~secured~~and ~~promissory~~ending ~~note~~eleven to(11) anmonths ~~accredited~~thereafter ~~investor~~(i.e. ~~made~~one ~~pursuant~~month prior to the ~~June~~Maturity ~~2018 Offering~~Date), the Company ~~issued~~may aat ~~two-year~~any ~~warrant to~~time ~~purchase~~upon upthirty to(30) ~~1,000,000~~days ~~shares~~prior ofwritten ~~the~~notice ~~Company’s~~repurchase ~~common~~any ~~stock~~or atall anoutstanding ~~exercise~~Notes ~~price~~without ofpenalty ~~$1.00 per~~or ~~share.~~premium; ~~The~~provided, ~~relative~~that ~~fair value of~~ the ~~debt~~holder ~~and~~may ~~warrant recorded~~convert ~~resulted~~the inNote ~~debt~~prior ~~discount~~to ofthe ~~$414,416 upon~~end ~~execution~~ of the ~~promissory~~Notice ~~note~~Period.

InThe ~~July 2018,~~Notes inare ~~connection~~secured ~~with~~by ~~issuance~~all assets of athe $1Company and its subsidiaries,~~050,000~~ ~~secured~~and ~~promissory~~are ~~note~~subordinate to ~~accredited~~ ~~investors~~the ~~made~~security ~~pursuant~~interest granted to holders of the ~~June~~Series ~~2018~~A ~~Offering,~~Notes ~~the~~and ~~Company~~Series B Notes previously issued aby ~~two-year~~the ~~warrant to~~Company. ~~purchase~~The upNotes toare ~~1,050,000~~subject ~~shares~~to ofcertain ~~the~~covenants ~~Company’s~~and ~~common~~other ~~stock~~provisions atcustomary anfor ~~exercise~~a ~~price~~transaction of ~~$1.00 per~~this ~~share~~nature. The ~~relative~~Company ~~fair~~received ~~value~~$175,000 ofin ~~the~~proceeds ~~debt~~pursuant ~~and~~to ~~warrant recorded~~the ~~resulted~~issuance inof ~~debt~~Notes ~~discount~~through ofDecember ~~$435~~31,~~271 upon~~ ~~execution~~2019 ofand ~~the~~incurred ~~promissory~~no ~~note~~broker fees.

In November 2018, the Company received $250,000 as an advance on inventory purchases from an affiliate of a related party.

On February 20, 2018, BAM Inc. and Pedro Lichtinger Waisman, Isaac Lichtinger Waisman and Victor Lichtinger Waisman (the “Lichtinger Group”) entered into a License and Business Development Agreement Mexico, effective as of February 13, 2018 (the “Agreement”). Following consummation of the Agreement, the Lichtinger Group formed a company in Mexico, Agro Space Tech SA de CV de RV (“Agro Space”), to which BAM will receive a twenty percent (20%) equity ownership interest. BAM received $100,000 following execution of the Agreement, to purchase shares of the Company in connection with the Company’s ongoing private placement of shares of its common stock for USD $3.00 per share.

Table of Contents

Without consideration of any revenue or additional fundraising, at the Company’s current rate of expenditure, we expect that our current capital will not be sufficient to cover our future operating costs for twelve months.

The sales cycle for our product BAM-FX™ in agriculture markets is generally two to three growing seasons. We have completed our second season and with certain growers, our third season, of validation and testing as a commercial product and believe that positive trial results on growers’ crops have contributed to product awareness. However, as important as the positive trial results are, third-party validation of the product’s performance and scientific proof of the product’s mode of action are equally important to our channel partners in their purchasing decisions. The scientific studies, which were undertaken in 2016, are expected to continue during 2018. We believe that the combination of validation, testing and technical studies carried out over the past years will lead to revenue generation and growth in 2018.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

For a discussion of our accounting policies and related items, please see the Notes to the unaudited ~~Condensed~~consolidated ~~Consolidated~~ Financial Statements, included in Note 1.

Item 3. Quantitative & Qualitative Disclosures about Market Risks

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide the information required by this item.

Table of Contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report (the “Evaluation Date”), the Company carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Principal ~~Accounting~~Financial Officer (our Chief Executive Officer and Chief Financial Officer, respectively), of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15 under the ~~Securities~~ Exchange Act ~~of 1934, as amended (the “Exchange Act”)~~. Based upon this evaluation, our Chief Executive Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures were not effective to provide reasonable assurance that (i) information required to be disclosed in the reports that are filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified by the SEC’s rules and forms and (ii) our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to our management including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that the Company’s disclosure controls and procedures will detect or uncover every situation involving the failure of persons within the Company to disclose material information otherwise required to be set forth in the Company’s periodic reports. The Company engaged a financial reporting consultant during the second quarter of 2020 to assist with the review of the Company's financial reporting requirements for future periodic reports.

Changes in Internal Control Over Financial Reporting

There were no changes in internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the ~~nine~~three months ended ~~September~~March 3031, ~~2018~~2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3034

Table of Contents

PART II OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any current or pending legal proceedings.

Item 1A. Risk Factors

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide the information required by this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The transactions below were exempt from the registration requirements of the Securities Act in reliance upon Section 4(a)(2) of the Securities Act of 1933, as amended, or Regulation D promulgated thereunder the Securities Act. All proceeds received in connection with any of the following transactions, as applicable, were used for general working capital purposes.

OnIn ~~June~~December ~~29,~~ 2018, ~~the~~and ~~Company~~January ~~initiated a new private offering of its securities (the “June 2018 Offering”) to certain prospective accredited investors~~2019, ~~including~~in ~~certain~~connection ~~members~~with of the ~~Board~~issuance of ~~Directors and/or their respective affiliates, consisting of up to $2,000,000 of 10% secured~~ convertible promissory notes ~~(the~~to ~~“June~~an ~~2018~~accredited ~~Offering Notes”)~~investor, ~~and~~the ~~two~~Company issued five-year warrants to purchase up to 2200,000~~,000~~ shares, in aggregate, of the Company’s common stock at an exercise price of $1.~~00 per share (the “June 2018 Offering Warrants”)~~75. An ~~accredited~~The ~~investor~~secured ~~and~~convertible ~~member~~promissory ofnotes ~~our~~are ~~Board~~convertible ofat ~~Directors~~a ~~provided~~conversion ~~additional~~price ~~funding~~equal of $250,000 on July 2, 2018 and an additional $250,000 on July 17, 2018, and the Company issued June 2018 Offering Notes in exchange therefore, with maturity dates of July 2, 2020 and July 17, 2020, respectively, and June 2018 Offering Warrants to ~~purchase, in~~ the ~~aggregate,~~lesser ~~up to 500,000 shares~~ of ~~the Company’s common stock. In addition, during July 2018, the Company received, in the aggregate,~~ $550,000 from seven other current shareholders and issued June 2018 Offering Notes in exchange therefore, and June 2018 Offering Warrants to purchase, in the aggregate, up to 550,000 shares of the Company’s common stock3. ~~Pursuant~~00 toor ~~the~~a ~~June~~“variable ~~2018~~conversion ~~Offering,~~price” inrepresenting ~~the~~a ~~aggregate,~~thirty-five ~~the~~percent ~~Company~~(35%) ~~issued~~discount ~~June 2018 Offering Notes having an aggregate principal balance of $2,050,000, and June 2018 Offering Warrants~~ to ~~purchase up to 2,050,000 shares of~~ the ~~Company’s~~market ~~common stock~~price. ~~The June 2018 Offering terminated on July 31, 2018.~~

~~During the~~Subsequent ~~three~~to ~~months~~December ~~ended September 30~~31, 2018, the Company issued ~~fully~~10 ~~vested, non-forfeitable five-~~year ~~warrants~~stock options to purchase ~~shares~~100,000 ~~of the Company’s~~ common ~~stock~~shares at an exercise price of $3.00 per ~~share (“Provider Warrants”) to employees and consultants for services rendered to purchase, in the aggregate, up to 95,000 shares of the Company’s~~ common ~~stock. Following~~share ~~September 30, 2018, the Company issued Provider Warrants~~ to ~~purchase, in the aggregate, up to 40,000 shares of the Company’s common stock to employees and~~ consultants for services ~~rendered~~. ~~During 2018, in the aggregate, the Company has issued Provider Warrants to purchase up to 425,000 shares of the Company’s common stock to employees and consultants for services rendered.~~

Subsequent to December 31, 2018, the Company issued 225,000 shares of common stock to consultants for services.

Subsequent to March 31, 2019, certain consultants and former employees exercised warrants in a cashless exercise resulting in the issuance of 146,248 shares of the Company’s common stock.

On January 2019, the Company received $100,000 from Michael T. Smith a member of our Board of Directors, and in exchange the Company issued an unsecured promissory note dated January 2019. The note bears interest at the rate of ten percent (10%) per annum, payable quarterly in cash. The note is payable in full plus all unpaid interest thereon, by April 18, 2019. The note contains a contingent conversion feature that allows the value of the note to be converted at $3 per share or such lower price at which the Company has issued stock subsequent to May 2, 2019, if any part of the principle balance is paid. No beneficial conversion feature existed at the issuance date of the note.

In February 2019, the Company issued fully vested, non-forfeitable warrants to purchase 75,000 common shares at an exercise price of $3.00 per common share to consultants for services.

On March 15, 2019, a shareholder loaned the Company $50,000 and in exchange was issued 2,000 shares of the Company’s stock. The loan was subsequently paid.

In connection with the private offerings noted above, the Company engaged a broker/dealer, Livingston Securities, LLC, to assist as placement agent for the securities. On November 16, 2018, the Company entered into a Placement Agent’s Agreement in connection with a proposed November 2018 private offering. The Company terminated the agreement on March 26, 2019. No underwriters were involved in the foregoing issuances of securities. Each of the above transactions was exempt from the registration requirements of the Securities Act in reliance upon Section 4(a)(2) of the Securities Act or Regulation D promulgated under the Securities Act. The recipient of the securities in each of these transactions represented his, her or its intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates or book-entry positions representing the shares issued in each of these transactions. In each case, the recipient had adequate access, through his, her or its relationship with the Company, to information about the Company.

Item 3. Defaults upon Senior Securities

None.

~~Item~~ITEM 54. ~~Other~~MINE ~~Information~~SAFETY DISCLOSURES

None.

ITEM 5. Other Information

None.

Table of Contents

ITEM 6. EXHIBITS

No.	Description of Exhibit	Note
3.1	Certificate of Incorporation, Amendments to Articles of Incorporation and Articles of Merger	(2)
3.2	Second Amended and Restated By-Laws of the Company	(3)
10.1	~~Form~~Promissory ofNote, ~~10%~~dated ~~Secured~~January ~~Convertible~~16, ~~Promissory~~2018, ~~Note~~issued ~~used~~by in the ~~June~~Company ~~2018~~to ~~Offering~~Rio Vista Investments, LLC.	(4)
10.2	~~Form~~Warrant, ofdated ~~Warrant~~January ~~used~~18, in2018, issued by the ~~June~~Company ~~2018~~to ~~Offering~~Rio Vista Investments, LLC.	(4)
10.3	Promissory Note, dated January 19, 2018,	(4)
10.4	Warrant, dated January 19, 2018	(4)
10.6	Promissory Note, dated March 8, 2018, issued by the Company to Michael T. Smith.	(5)
10.7	Warrant, dated March 9, 2018, issued by the Company to Michael T. Smith.	(5)
10.8	Promissory Note, dated March 12, 2018, issued by the Company to Boies Partners, Inc.	(5)
10.9	Warrant, dated March 12, 2018, issued by the Company to Boies Partners, Inc.	(5)
31.1	Certification of Principal Executive Officer and Principal Financial and Accounting Officer as required by Rule 13a-14 or 15d-14 of the Exchange Act, as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	(1)
32.1	Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	(1)
101	The following materials from the Company’s Quarterly Report on Form 10-Q for the three-months ended ~~September~~March 3031, ~~2018~~2019 are formatted in XBRL (eXtensible Business Reporting Language): (i) the Balance Sheets, (ii) the Statements of Operations, (iii) the Statements of Cash Flows, and (iv) the Notes to the ~~Condensed Consolidated~~ Financial Statements.	(1)

(1) Filed herewith.

(1)	Filed herewith.
(2)	Incorporated by reference from the Company’s Registration Statement on Form 10, filed with the SEC on December 29, 2014.
(3)	Incorporated by reference from the Company’s Current Report on Form 8-K, filed with the SEC on October 5, 2015.
(4)	Incorporated by reference from the Company’s Current Report on Form 8-K, filed with the SEC on January 25, 2018.
(5)	Incorporated by reference from the Company’s Current Report on Form 8-K, filed with the SEC on March 14, 2018.

~~(2) Incorporated by reference from the Company’s Registration Statement on Form 10, filed with the SEC on December 29, 2014.~~36

(3) Incorporated by reference from the Company’s Current Report on Form 8-K, filed with the SEC on October 5, 2015.

(4) Incorporated by reference from the Company’s Current Report on Form 8-K, filed with the SEC on July 13, 2018.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZERO GRAVITY SOLUTIONS, INC.
	(Registrant)
Dated: November 19, 2018	By:	/s/ Timothy A. Peach
Dated: August 18, 2020	By:	/s/ Timothy A. Peach
		Timothy A. Peach, Acting Chief Executive Officer
		(Principal Executive Officer) Chief Financial Officer
		and Chief Financial Officer
		(Principal Accounting Officer)
		(Principal Executive Officer and Principal Financial Officer)

3237

Filing Compare · Zero Gravity Solutions, Inc.